2024


  1. Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2024). [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. Pathologie (Heidelb), 45(1), 51-58.
     
  2. Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2024). [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. Pathologie (Heidelb), 45(1), 51-58.
     
  3. Golombek T, Hegewald N, Schnabel A, Fries H, Lordick F (2024). Stability of End-of-Life Care Wishes and Gender-Specific Characteristics of Outpatients with Advanced Cancer under Palliative Therapy: A Prospective Observational Study. Oncol Res Treat, 47(5), 189-197.
     
  4. Stocker G, Hacker U, Lordick F (2024). [Immunotherapy for gastrointestinal cancer]. Dtsch Med Wochenschr, 149(8), 432-439.
     
  5. Jenke R, Oliinyk D, Zenz T, Körfer J, Schäker-Hübner L, Hansen FK, Lordick F, Meier-Rosar F, Aigner A, Büch T (2024). HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer. Biochem Pharmacol, 225(), 116257.
     
  6. Lordick F, Van Cutsem E, Shitara K, Xu RH, Ajani JA, Shah MA, Oh M, Ganguli A, Chang L, Rhoten S, Bhattacharya P, Matsangou M, Park JW, Pophale R, Ranganath R, Kang YK (2024). Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open, 9(8), 103663.
     
  7. Lordick F, Rha SY, Muro K, Yong WP, Lordick Obermannová R (2024). Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives. Cancers (Basel), 16(19), 1-14.
     
  8. Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Obermannová RL, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Sanchez CB, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E (2024). Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Ann Oncol, (), 3-29.
     
  9. Kerle IA, Scheuble AM, Kobitzsch B, Stocker G, Hiller GGR, Badendick M, William D, Krueger A, Gross T, Koegler A, Hartig A, Richter D, Aust DE, Schroeck E, Heining C, Glimm H, Hacker UT (2024). Exceptional Response of BRAF(V600E)-Mutated Acinar Cell CUP to BRAF/MEK Inhibition. JCO Precis Oncol, 8(), e2400030.
     
  10. Kobitzsch B, Bischof M, Hacker U, Stocker G, Lordick F (2024). Systemic therapy of stage IV gastric cancer?current developments Springer Nature Link, 30, 1116-1121.
     
  11. Kobitzsch B, Stocker G, Hacker UT, Junge S, Pauligk C, Al-Batran SE, Goetze TO, Lordick F (2024). SAGA?a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma ESMO Gastrointestinal Oncology, 4, 1-5.
     
  12. Lordick F (2024). Wirksamere Therapien bei Magenkrebs erreichen die Praxis. Im Fokus Onkologie, 27 , 3.
     
  13. Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2024). Standardisierte und qualitätsgesicherte prädiktive PD-L1-Testung im oberen Gastrointestinaltrakt Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version Die Pathologie, 45, 51-58.
     
  14. Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart JE, Hoogenboom JD, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P (2024). Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Ann Oncol, 35(4), 404-406.
     
  15. Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2024). [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. Pathologie (Heidelb), 45(1), 51-58.
     
  16. Wang J, Sun N, Kunzke T, Shen J, Feuchtinger A, Wang Q, Meixner R, Gleut RL, Haffner I, Luber B, Lordick F, Walch A (2024). Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer. Br J Cancer, 130(6), 1036-1045.
     
  17. Olbrich A, Niemeyer J, Seiffert H, Ebel S, Gros O, Lordick F, Forstmeyer D, Seehofer D, Rademacher S, Denecke T, Matz-Soja M, Berg T, van Bömmel F (2024). The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol, 150(2), 81.
     
  18. Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F, Bhandari P, Kawakubo H, Kodera Y, Terashima M, Muro K, Takeuchi H, Mansfield PF, Kurokawa Y, So J, Mönig SP, Shitara K, Rha SY, Janjigian Y, Takahari D, Chau I, Sharma P, Ji J, de Manzoni G, Nilsson M, Kassab P, Hofstetter WL, Smyth EC, Lorenzen S, Doki Y, Law S, Oh DY, Ho KY, Koike T, Shen L, van Hillegersberg R, Kawakami H, Xu RH, Wainberg Z, Yahagi N, Lee YY, Singh R, Ryu MH, Ishihara R, Xiao Z, Kusano C, Grabsch HI, Hara H, Muk (2024). Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023. Gastric Cancer, 27(3), 401-425.
     
  19. Rahbari NN, Biondo S, Frago R, Feißt M, Kreisler E, Rossion I, Serrano M, Jäger D, Lehmann M, Sommer F, Dignass A, Bolling C, Vogel I, Bork U, Büchler MW, Folprecht G, Kieser M, Lordick F, Weitz J (2024). Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. J Clin Oncol, 42(13), 1531-1541.
     
  20. Springer F, Maier A, Friedrich M, Raue JS, Finke G, Lordick F, Montgomery G, Esser P, Brock H, Mehnert-Theuerkauf A (2024). Digital Therapeutic (Mika) Targeting Distress in Patients With Cancer: Results From a Nationwide Waitlist Randomized Controlled Trial. J Med Internet Res, 26(), 51949.
     
  21. Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds JV, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshoff MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs C, Slingerland M, Voncken FEM, (2024). European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer, 204(), 114062.
     
  22. Shitara K, Shah MA, Lordick F, Bang YJ, Ilson D, Van Cutsem E, Enzinger P, Kim SS, Klempner SJ, Moran D, Park JW, Bhattacharya P, Ajani JA, Xu RH (2024). Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol, 20(26), 1861-1877.
     
  23. Wichmann G, Wald T, Pirlich M, Stoehr M, Zebralla V, Kuhnt T, Nicolay NH, Hambsch P, Krücken I, Hoffmann KT, Lordick F, Kluge R, Wiegand S, Dietz A (2024). Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol. Front Oncol, 14(), 1394691.
     
  24. Goerling U, Ernst J, Esser P, Haering C, Hermann M, Hornemann B, Hövel P, Keilholz U, Kissane D, von dem Knesebeck O, Lordick F, Springer F, Zingler H, Zimmermann T, Engel C, Mehnert-Theuerkauf A (2024). Estimating the prevalence of mental disorders in patients with newly diagnosed cancer in relation to socioeconomic status: a multicenter prospective observational study. ESMO Open, 9(8), 103655.
     
  25. Ronellenfitsch U, Friedrichs J, Barbier E, Bass GA, Burmeister B, Cunningham D, Eyck BM, Grilli M, Hofheinz RD, Kieser M, Kleeff J, Klevebro F, Langley R, Lordick F, Lutz M, Mauer M, Michalski CW, Michl P, Nankivell M, Nilsson M, Seide S, Shah MA, Shi Q, Stahl M, Urba S, van Lanschot J, Vordermark D, Walsh TN, Ychou M, Proctor T, Vey JA (2024). Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis. JAMA Netw Open, 7(8), 2425581.
     
  26. Cella CA, Djulbegovic B, Hozo I, Lordick F, Bagnardi V, Frassoni S, Gervaso L, Fazio N (2024). Comparison of Khorana vs. ONKOTEV predictive score to individualize anticoagulant prophylaxis in outpatients with cancer. Eur J Cancer, 209(), 114234.
     
  27. Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O'Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J (2024). Preoperative Chemoradiotherapy for Resectable Gastric Cancer. N Engl J Med, 391(19), 1810-1821.
     
  28. Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH (2024). Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med, 391(12), 1159-1162.
     
  29. Li M, Meindl-Beinker NM, Maenz M, Betge J, Schulte N, Zhan T, Hofheinz RD, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Bauer H, Ebert MP, Haertel N (2024). Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study. J Geriatr Oncol, 15(7), 101838.
     
  30. Thuss-Patience P, Högner A, Goekkurt E, Stahl M, Kretzschmar A, Götze T, Stocker G, Reichardt P, Kullmann F, Pink D, Bartels P, Jarosch A, Hinke A, Schultheiß C, Paschold L, Stein A, Binder M (2024). Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial. JAMA Netw Open, 7(1), 2352830.
     
  31. Araujo AE, Bentler M, Perez Garmendia X, Kaleem A, Fabian C, Morgan M, Hacker UT, Büning H (2024). Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies. Hum Gene Ther, 35, 586-603.
     
  32. Lorenz L, Zenz T, Oliinyk D, Meier-Rosar F, Jenke R, Aigner A, Büch T (2024). Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes. Pharmaceuticals (Basel), 17(8), 1-16.
     
  33. Walther M, Jenke R, Aigner A, Ewe A (2024). Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6. Eur J Pharm Biopharm, 197(), 114232.
     
  34. Mehdorn, M, Kobitzsch, B, Rabe, SM, Gockel I, Stelzner S (2024). Kolonkarzinom Springer Nature Link, 46, 137-146.
     
  35. Müller E, Gahr S, Schnabel A, Müller MJ, Sölder P, Tewes M, Roch C (2024). Screening auf Bedarf an spezialisierter Palliativversorgung Know-how und Screeningtools Die Onkologie, 09, 1.
     
  36. Oechsle K, Berendt J, Gebert T, Heckel M, Hentschel L, Hornemann B, Jentschke E, Neukirchen M, van Oorschot B, Rechenmacher M, Schnabel A, Steffen Simon, Stiel S, Ullrich A (2024). Mitbetreuung der Angehörigen von Patient:innen mit einer nicht heilbaren Krebserkrankung im Erkrankungsverlauf Die Onkologie, 30, 1053-1061.
     
  37. Renz BW, Lordick F, Angele MK (2024). Fortschritte in der Behandlung des Magenkarzinoms ? ein ganzheitlicher Ansatz. Die Onkologie, 30, 1076-1080.
     
  38. Hoeppner J, Brunner T, Lordick F, Schmoor C, Kulemann B, Neumann UP, Folprecht G, et al (2024). Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). Journal of Clinical Oncology, 42, 17.
     
  39. Shitara K, Cutsem E, Lordick F, Enzinger PC, Ilson DH, Shah MA, et al (2024). Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2?, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Journal of Clinical Oncology, 42, 16.
     
  40. Cabeza Segura M, Schooten VT, Ferreira R, Ruiz E, Caballero C, O Connor JMR, Riquelme A, Owen GI, Garrido M , Díez García M, Alsina Maqueda M, Lordick F, Farrés J, Miralles A, Dienstmann R, Carneiro F, Cervantes A, Consortium L, Derks S, Fleitas TC (2024). 226P Profiling of gastric adenocarcinomas from EU and LATAM countries identifies distinct tumor immune subgroups and a central role of the tumor microbiome in shaping the immune microenvironment ESMO Immuno-Oncology and Technology, 14, 00.
     
  41. Pouyiourou M, Zaun G, Hacker UT, Stenzinger A, Bochtler T, Krämer A, et al (2024). 185P Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP) ESMO Annals of Oncology, 35, 289-290.
     
  42. Porschen R, Gockel I, Lordick F, Ebert M (2024). Aktualisierte S3-Leitlinie ?Diagnostik und Therapie der Plattenepithel- und Adenokarzinome des Ösophagus (Version 4.0)? Die Onkologie, 30, 423-432.
     
  43. Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH (2024). Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med, 391(12), 1159-1162.
     
  44. Brunner TB, Lordick F, Schmoor C, Schmidberger H, Kirste S, Rieken S, Petersen C, Nicolay NH, Fokas E, Dunst J, Rades D, Eble MJ, Krause M, Roedel C, Medenwald D, Niehoff P, Wittig-Sauerwein A, Baues C, Grosu A, Hoeppner J (2024). Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC ? a Randomised Controlled Prospective Multicentre Phase III Trial International Journal of Radiation Oncology*Biology*Physics, 120, 6.
     
  45. Zenz T, Jenke R, Thieme R, Kahl T, Borchardt H, Gockel I, Hansen FK, Aigner A, Büch TR (2024). The HDAC Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2 Amplified Tumors and in Combination Therapies. Cancer Res Treat, (), 00.
     
  46. Tozzi F, Rashidian N, Ceelen W, Callebout E, Hübner M, Sgarbura O, Willaert W (2024). Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: A Delphi consensus statement. Eur J Surg Oncol, 50(6), 108346.
     


    47. 2023


  47. Ben-Aharon I, van Laarhoven HWM, Fontana E, Obermannova R, Nilsson M, Lordick F (2023). Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. Cancer Discov, 13(3), 538-551.
     
  48. Topf V, Kheifetz Y, Daum S, Ballhausen A, Schwarzer A, Trung KV, Stocker G, Aigner A, Lordick F, Scholz M, Knödler M (2023). Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors. J Cancer Res Clin Oncol, 149(10), 6989-6998.
     
  49. Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö (2023). Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol, 149(9), 5937-5950.
     
  50. Stocker G, Lorenzen S, Ettrich T, Herz AL, Longo F, Kiani A, Venerito M, Trojan J, Mahlberg R, Moosmann N, Chibaudel B, Kubicka S, Greil R, Daum S, Geissler M, Larcher-Senn J, Keller G, Lordick F, Haag GM (2023). S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial. ESMO Open, 8(3), 101572.
     
  51. Schnabel A, Lordick F, Oberth P, Neuschulz M, Lehmann-Laue A, Mehnert-Theuerkauf A, Hinz A (2023). Supportive care needs and health-related quality of life in cancer patients receiving palliative care. Front Psychol, 14(), 1166801.
     
  52. Lordick F, Merz M, Büch E, Aigner A (2023). Antibody-Drug Conjugates as a Targeted Therapeutic Approach Across Entities in Oncology. Dtsch Arztebl Int, 120(19), 329-336.
     
  53. Krause A, Stocker G, Gockel I, Seehofer D, Hoffmeister A, Bläker H, Denecke T, Kluge R, Lordick F, Knödler M (2023). Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. J Cancer Res Clin Oncol, 149(3), 1231-1240.
     
  54. Lordick F, Wörmann B (2023). National guidelines for gastric cancer: redundant or needed? Gastric Cancer, (), 1 - 9 .
     
  55. Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, Gockel I, Köberle D, Lorenzen S, Möhler M, Pritzkuleit R, Stahl M, Thuss-Patience P, Wöll E, Zander T, Maschmeyer G (2023). German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer, (), 1 - 39.
     
  56. Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, Bläker H, Wittekind C, Lordick F (2023). Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol, 149(3), 1319-1329.
     
  57. Hacker UT (2023). On the way to developing AAV-based vaccines as novel tools for cancer immunotherapy. Mol Ther Methods Clin Dev, 28(), 394-395.
     
  58. Potthoff K, Dechow T, Lorenzen S, Reinacher-Schick A, Binninger A, Matillon C, Siebenbach HU, Haffner I, Hacker U, Bläker H, Lordick F (2023). SAPHIR: real-world clinical research platform for molecular testing, treatment, and clinical and patient-reported outcomes in patients with gastroesophageal cancer in Germany ESMO Real World Data and Digital Oncology, Volume 2, 6.
     
  59. Lordick F, Merz M, Aigner A (2023). In Reply. Dtsch Arztebl Int, 120(38), 643.
     
  60. Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, Bläker H, Wittekind C, Lordick F (2023). Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol, 149(3), 1319-1329.
     
  61. Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshof MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs CT, Slingerland M, Voncken FEM, Hartgrink H (2023). Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer, 185(), 28-39.
     
  62. Boeschen M, Kuhn CK, Wirtz H, Seyfarth HJ, Frille A, Lordick F, Hacker UT, Obeck U, Stiller M, Bläker H, von Laffert M (2023). Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C. Lung Cancer, 184(), 107361.
     
  63. Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Shapiro J, Vernerey D, Smithers BM, Walsh T, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, de Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Roth J, Gebski V, Burmeister B, Paoletti X, van Sandick J, Fu J, Pignon JP, Ducreux M, Michiels S (2023). Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin Oncol, 41(28), 4535-4547.
     
  64. Kogel A, Machatschek M, Scharschmidt R, Wollny C, Lordick F, Ghanem M, Laufs U, Fikenzer S (2023). Physical exercise as a treatment for persisting symptoms post-COVID infection: review of ongoing studies and prospective randomized controlled training study. Clin Res Cardiol, (), 1-11.
     
  65. Falz R, Bischoff C, Thieme R, Tegtbur U, Hillemanns P, Stolzenburg JU, Aktas B, Bork U, Weitz J, Lässing J, Leps C, Voß J, Lordick F, Schulze A, Gockel I, Busse M (2023). Effect of home-based online training and activity feedback on oxygen uptake in patients after surgical cancer therapy: a randomized controlled trial. BMC Med, 21(1), 293.
     
  66. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH (2023). Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med, 29(8), 2133-2141.
     
  67. Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pereira C, Knapp M, Schüller V, Quaas A, Grabsch HI, Trautmann J, Malecka-Wojciesko E, Mokrowiecka A, Speller J, Mayr A, Schröder J, Hillmer AM, Heider D, Lordick F, Pérez-Aísa Á, Campo R, Espinel J, Geijo F, Thomson C, Bujanda L, Sopeña F, Lanas Á, Pellisé M, Pauligk C, Goetze TO, Zelck C, Reingruber J, Hassanin E, Elbe P, Alsabeah S, Lindblad M, Nilsson M, Kreuser N, Thieme R, Tavano F, Pastorino R, (2023). Corrigendum to "Dissecting the genetic heterogeneity of gastric cancer". EBioMedicine, 94(), 104709.
     
  68. Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J (2023). The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med, 29(6), 1298-1301.
     
  69. Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E (2023). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open, 8(3), 101567.
     
  70. Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pereira C, Knapp M, Schüller V, Quaas A, Grabsch HI, Trautmann J, Malecka-Wojciesko E, Mokrowiecka A, Speller J, Mayr A, Schröder J, Hillmer AM, Heider D, Lordick F, Pérez-Aísa Á, Campo R, Espinel J, Geijo F, Thomson C, Bujanda L, Sopeña F, Lanas Á, Pellisé M, Pauligk C, Goetze TO, Zelck C, Reingruber J, Hassanin E, Elbe P, Alsabeah S, Lindblad M, Nilsson M, Kreuser N, Thieme R, Tavano F, Pastorino R, (2023). Dissecting the genetic heterogeneity of gastric cancer. EBioMedicine, 92(), 104616.
     
  71. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA (2023). Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet, 401(10389), 1655-1668.
     
  72. Lorenzen S, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Knorrenschild JR, Illerhaus G, Dechow T, Moehler M, Moulin JC, Pink D, Stahl M, Schaaf M, Goetze TO, Al-Batran SE (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer, 23(1), 561.
     
  73. Baretton GB, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Moehler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2023). Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J Cancer Res Clin Oncol, 149(17), 16231-16238.
     
  74. Alberti A, Stocker G, Lordick F, Hacker UT, Kobitzsch B, Haffner I, Baiocchi GL, Zamparini M, Tiberio GAM, Baronchelli C, Caruso A, Bossi P, Berruti A (2023). Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study). Front Oncol, 13(), 1276138.
     
  75. Franke AC, Hardet R, Prager L, Bentler M, Demeules M, John-Neek P, Jäschke NM, Ha TC, Hacker UT, Adriouch S, Büning H (2023). Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy. Mol Ther Methods Clin Dev, 29(), 238-253.
     
  76. Bentler M, Hardet R, Ertelt M, Rudolf D, Kaniowska D, Schneider A, Vondran FWR, Schoeder CT, Delphin M, Lucifora J, Ott M, Hacker UT, Adriouch S, Büning H (2023). Modifying immune responses to adeno-associated virus vectors by capsid engineering. Mol Ther Methods Clin Dev, 30(), 576-592.
     
  77. Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A (2023). Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun, 14(1), 6761.
     
  78. Wiegand S, Wichmann G, Vogt J, Vogel K, Franke A, Kuhnt T, Lordick F, Scheuble AM, Hambsch P, Brossart P, Bauernfeind FG, Kaftan H, Maschmeyer G, Paland M, Münter M, Lewitzki V, Rotter N, Stromberger C, Beck M, Dommerich S, Gauler TC, Hapke G, Guntinas-Lichius O, Schröder U, Görner M, Hautmann MG, Steger F, Tamaskovics B, Schmiedeknecht A, Dietz A (2023). Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial. Front Oncol, 13(), 1128176.
     
  79. Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS (2023). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 24(11), 1181-1195.
     
  80. Lordick F, Merz M, Aigner A (2023). In Reply. Dtsch Arztebl Int, 120(38), 643.
     
  81. Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D (2023). Development and characterization of NILK-2301, a novel CEACAM5xCD3 ?? bispecific antibody for immunotherapy of CEACAM5-expressing cancers. J Hematol Oncol, 16(1), 117.
     
  82. Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart JE, Hoogenboom JD, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P (2023). Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Ann Oncol, (), 4.
     
  83. Alberti A, Stocker G, Lordick F, Hacker UT, Kobitzsch B, Haffner I, Baiocchi GL, Zamparini M, Tiberio GAM, Baronchelli C, Caruso A, Bossi P, Berruti A (2023). Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study). Front Oncol, 13(), 1276138.
     
  84. Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A (2023). Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun, 14(1), 6761.
     
  85. Boeschen M, Kuhn CK, Wirtz H, Seyfarth HJ, Frille A, Lordick F, Hacker UT, Obeck U, Stiller M, Bläker H, von Laffert M (2023). Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C. Lung Cancer, 184(), 107361.
     


    86. 2022


  86. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC (2022). Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 33(10), 1005-1020.
     
  87. Lordick F, Obermannová R, Smyth EC (2022). Targeting HER2 for localised oesophageal cancer. Lancet Oncol, 23(2), 188-190.
     
  88. Pfrepper C, Knödler M, Schorling RM, Seehofer D, Petros S, Lordick F (2022). Predictors for thromboembolism in patients with cholangiocarcinoma. J Cancer Res Clin Oncol, 148(9), 2415-2426.
     
  89. Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, Zdrazilova-Dubska L, Valik D, Lordick F (2022). Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol, 33(7), 685-692.
     
  90. Pavlakis N, Tincknell G, Lim LE, Muro K, Obermannova R, Lorenzen S, Chua YJ, Jackson C, Karapetis CS, Price T, Chantrill L, Segelov E, Lordick F (2022). European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. Ther Adv Med Oncol, 14(), 17588359221118874.
     
  91. Krause A, Stocker G, Gockel I, Seehofer D, Hoffmeister A, Bläker H, Denecke T, Kluge R, Lordick F, Knödler M (2022). Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. J Cancer Res Clin Oncol, (), 7-15.
     
  92. Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, Hook S, Schmitz J, Bräsen JH, Franke AC, Olarewaju O, Brandenberger C, Talbot SR, Fangmann J, Hacker UT, Odenthal M, Ott M, Piiper A, Büning H (2022). Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers (Basel), 14(2), 14-27.
     
  93. Lordick F, Hacker U, Hoffmeister A, Bläker H, Gockel I (2022). [What is confirmed in the treatment of colon cancer?]. Inn Med (Heidelb), 63(12), 1250-1256.
     
  94. Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A (2022). Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin Cancer Res, 28(13), 2865-2877.
     
  95. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E (2022). Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol, 40(26), 3065-3076.
     
  96. Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP, D'Ugo D, Haustermans K, van Cutsem E, van Hillegersberg R, van Rossum PSN (2022). Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer, 166(), 254-269.
     
  97. Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkins MA, Smyth E, Markar S, Hanna GB, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns CJ, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick JW, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot LV, Kolodziejczyk P, Polkowski WP, Alsina M, Pera M, Kanonnikoff TF, Nils (2022). Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer, 164(), 18-29.
     
  98. Myer NM, Shitara K, Chung HC, Lordick F, Kelly RJ, Szabo Z, Cao ZA, Leong S, Ilson DH, Weichert W (2022). Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. J Cancer Res Clin Oncol, 148(8), 2023-2043.
     
  99. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC (2022). Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 33(10), 992-1004.
     
  100. Zimmermann T, Dreismann L, Ginger V, Wenzel M, Hornemann B, Dietzsch F, Sura C, Bornhäuser M, Mehnert-Theuerkauf A, Heyne S, Gockel I, Lordick F, Franzke A, Weitz J, Vogel A (2022). Study protocol: the OptiScreen-Study: optimized psycho-oncological care-from screening to intervention. J Cancer Res Clin Oncol, (), 1-12.
     
  101. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K (2022). T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol, (), 1124-1134.
     
  102. Olbrich A, Gros O, Ebel S, Denecke T, Gößmann H, Linder N, Lordick F, Forstmeyer D, Seehofer D, Sucher R, Rademacher S, Niemeyer J, Matz-Soja M, Berg T, Bömmel FV (2022). Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas. Cancers (Basel), 14(19), 4807-4807.
     
  103. Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M (2022). Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. J Cancer Res Clin Oncol, (), 1-7.
     
  104. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D'Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R (2022). Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol, (), 748-798.
     
  105. Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, Bläker H, Wittekind C, Lordick F (2022). Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol, (), 39-51.
     
  106. Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks EM, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E (2022). Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res, (), 1-9.
     
  107. Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, Stahl M, Reichardt P, Sökler M, Pink D, Probst S, Hinke A, Goetze TO, Al-Batran SE (2022). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer, 165(), 48-57.
     
  108. Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC (2022). Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer, 150(8), 1341-1349.
     
  109. Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks E, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E (2022). Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res, (), 58-78.
     
  110. Unterrainer M, Deroose CM, Herrmann K, Moehler M, Blomqvist L, Cannella R, Caramella C, Caruso D, Chouhan MD, Denecke T, De la Pinta C, De Geus-Oei LF, Dulskas A, Eisenblätter M, Foley KG, Gourtsoyianni S, Lecouvet FE, Lopci E, Maas M, Obmann MM, Oprea-Lager DE, Verhoeff JJC, Santiago I, Terraz S, D'Anastasi M, Regge D, Laghi A, Beets-Tan RGH, Heinemann V, Lordick F, Smyth EC, Ricke J, Kunz WG (2022). Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation. Eur J Cancer, 176(), 193-206.
     
  111. Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang QL, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, Ferri L, Wong RK, O'Callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong FM, Chao YK, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R (2022). Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol, 12(), 917-961.
     
  112. Sgambato S, Passariello N, Paolisso G, Marano A, Buoninconti R, Tesauro P (2022). Effect of human calcitonin (hCT) on glucose- and arginine-stimulated insulin secretion. Acta Diabetol Lat, 23(1), 13-22.
     
  113. Ebert K, Haffner I, Zwingenberger G, Keller S, Raimúndez E, Geffers R, Wirtz R, Barbaria E, Hollerieth V, Arnold R, Walch A, Hasenauer J, Maier D, Lordick F, Luber B (2022). Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF. BMC Cancer, 22(1), 254-254.
     
  114. Schröder J, Chegwidden L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messman (2022). GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut, (), 21-26.
     
  115. Kuon J, Blasi M, Unsöld L, Vogt J, Mehnert A, Alt-Epping B, van Oorschot B, Sistermanns J, Ahlborn M, Ritterbusch U, Stevens S, Kahl C, Ruellan A, Matthias K, Kubin T, Stahlhut K, Heider A, Lordick F, Thomas M (2022). Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study. Support Care Cancer, 30(4), 3131-3140.
     
  116. Sivanathan V, Utz C, Thomaidis T, Förster F, Stahl M, Lordick F, Ibach S, Kanzler S, Adler A, Mönig SP, Schimanski CC, Ignee A, Dietrich CF, Galle PR, Moehler M (2022). Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial. Ultraschall Med, 43(5), 514-521.
     
  117. van Schooten TS, Derks S, Jiménez-Martí E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O'Connor JM, Esteso F, Farrés J, Mas JM, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T (2022). The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer, 22(1), 646.
     
  118. Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2022). Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer, 162(), 245-246.
     
  119. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2022). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, 45(2), 218-222.
     
  120. Schröder J, Chegwidden L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messman (2022). GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut, (), 326-336.
     
  121. Ebert MP, Meindl-Beinker NM, Gutting T, Maenz M, Betge J, Schulte N, Zhan T, Weidner P, Burgermeister E, Hofheinz R, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Gaiser T, Kather JN, Haertel N (2022). Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. Lancet Healthy Longev, 3(6), 417-427.
     
  122. Jansen-Winkeln B, Eberth J, Moulla Y, Mehdorn M, Niebisch S, Schierle K, Bläker H, Lordick F, Gockel I, Thieme R (2022). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study. J Cancer Res Clin Oncol, (), 1-11.
     
  123. Bernard M, Löbner M, Lordick F, Mehnert-Theuerkauf A, Riedel-Heller SG, Luck-Sikorski C (2022). Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour? BMC Womens Health, 22(1), 511.
     
  124. Kroese TE, Takahashi Y, Lordick F, van Rossum PSN, Ruurda JP, Lagarde SM, van Hillegersberg R, Verhoeven RHA, van Laarhoven HWM (2022). Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. Eur J Cancer, 179(), 65-75.
     
  125. Stolze T, Franke S, Haybaeck J, Moehler M, Grimminger PP, Lang H, Roth W, Gockel I, Kreuser N, Bläker H, Wittekind C, Lordick F, Vieth M, Veits L, Waidmann O, Lingohr P, Peitz U, Schildberg C, Kruschewski M, Vassos N, Goni E, Bruns CJ, Ridwelski K, Wolff S, Lippert H, Schumacher J, Malfertheiner P, Venerito M (2022). Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. J Cancer Res Clin Oncol, (), 1-11.
     
  126. Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, Hook S, Schmitz J, Bräsen JH, Franke AC, Olarewaju O, Brandenberger C, Talbot SR, Fangmann J, Hacker UT, Odenthal M, Ott M, Piiper A, Büning H (2022). Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers (Basel), 14(2), 1-19.
     
  127. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC (2022). Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, 22(1), 39-51.
     
  128. Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med, 387(3), 217-226.
     
  129. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol, 33(12), 1250-1268.
     
  130. Arndt V, Doege D, Fröhling S, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts C, Brossart P, Brucker SY, Brümmendorf TH, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, Lordick F, Peters C, Schadendorf D, Stilgenbauer S, Braun D, Seufferlein T, Nettekoven G, Baumann M (2022). Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie Forum, 37(5), 372-376.
     


    131. 2021


  131. Vogt J, Beyer F, Sistermanns J, Kuon J, Kahl C, Alt-Epping B, Stevens S, Ahlborn M, George C, Heider A, Tienken M, Loquai C, Stahlhut K, Ruellan A, Kubin T, Dietz A, Oechsle K, Mehnert-Theuerkauf A, van Oorschot B, Thomas M, Ortmann O, Engel C, Lordick F (2021). Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. Oncologist, 26(6), e1058-e1065.
     
  132. Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö (2021). Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+?gastroesophageal adenocarcinoma. Gastric Cancer, 24(3), 721-730.
     
  133. Jenke R, Reßing N, Hansen FK, Aigner A, Büch T (2021). Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel), 13(4), 634.
     
  134. Catanese S, Lordick F (2021). Targeted and immunotherapy in the era of personalised gastric cancer treatment. Best Pract Res Clin Gastroenterol, 50-51, 50-51.
     
  135. Körfer J, Lordick F, Hacker UT (2021). Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. Cancers (Basel), 13(20), 20-20.
     
  136. Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S, Decker T, Wittekind C, Lordick F (2021). HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J Clin Oncol, 39(13), 1468-1478.
     
  137. Catanese S, Beuchel CF, Sawall T, Lordick F, Brauer R, Scholz M, Ceglarek U, Hacker UT (2021). Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients. J Cachexia Sarcopenia Muscle, (), 18-21.
     
  138. Pfrepper C, Knödler M, Schorling RM, Seehofer D, Petros S, Lordick F (2021). Predictors for thromboembolism in patients with cholangiocarcinoma. J Cancer Res Clin Oncol, (), 432.
     
  139. Hacker U, Hoffmeister A, Lordick F (2021). [Gastric Cancer: diagnosis and current treatment strategies]. Dtsch Med Wochenschr, 146(23), 1533-1537.
     
  140. Falz R, Thieme R, Tegtbur U, Bischoff C, Leps C, Hillemanns P, Kohlhaw K, Klempnauer J, Lordick F, Stolzenburg JU, Aktas B, Weitz J, Bork U, Wimberger P, Thomas C, Biemann R, Jansen-Winkeln B, Schulze A, Gockel I, Busse M (2021). CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial. BMC Sports Sci Med Rehabil, 13(1), 15.
     
  141. Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon JC, Ziemer M, Kunz M (2021). Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Int J Mol Sci, 22(15), 8017.
     
  142. Wichmann G, Willner M, Kuhnt T, Kluge R, Gradistanac T, Wald T, Fest S, Lordick F, Dietz A, Wiegand S, Zebralla V (2021). Standardized Diagnostics Including PET-CT Imaging, Bilateral Tonsillectomy and Neck Dissection Followed by Risk-Adapted Post-Operative Treatment Favoring Radio-Chemotherapy Improve Survival of Neck Squamous Cell Carcinoma of Unknown Primary Patients. Front Oncol, 11(), 682088.
     
  143. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A (2021). Correction: Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS One, 16(5), 623.
     
  144. Brückner L, Reinshagen A, Hoang NA, Höhn AK, Lordick F, Bechmann I, Aktas B, Nel I, Kallendrusch S (2021). FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo. Cancers (Basel), 13(5), 956.
     
  145. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A (2021). Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS One, 16(2), 312.
     
  146. Gutsch D, Jenke R, Büch T, Aigner A (2021). Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy. Cells, 10(2), 272.
     
  147. Schaudinn A, Hudak A, Linder N, Reinhardt M, Stocker G, Lordick F, Denecke T, Busse H (2021). Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data. Obesity (Silver Spring), 29(2), 294-301.
     
  148. Gervaso L, Pellicori S, Cella CA, Bagnardi V, Lordick F, Fazio N (2021). Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. Ther Adv Med Oncol, 13, 17-21.
     
  149. Junk D, Krämer S, Broschewitz J, Laura H, Massa C, Moulla Y, Hoang NA, Monecke A, Eichfeld U, Bechmann I, Lordick F, Seliger B, Kallendrusch S (2021). Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition. Cell Death Discov, 7(1), 264.
     
  150. Hußtegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, Körfer J (2021). PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology, 10(1), 1960729.
     
  151. Gervaso L, Lordick F, Fazio N (2021). Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom? JAMA Oncol, (), 10-11.
     
  152. Kunzke T, Hölzl FT, Prade VM, Buck A, Huber K, Feuchtinger A, Ebert K, Zwingenberger G, Geffers R, Hauck SM, Haffner I, Luber B, Lordick F, Walch A (2021). Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer. Clin Transl Med, 11(9), 547.
     
  153. Catanese S, Beuchel CF, Sawall T, Lordick F, Brauer R, Scholz M, Ceglarek U, Hacker UT (2021). Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients. J Cachexia Sarcopenia Muscle, (), 17-21.
     
  154. Sender A, Friedrich M, Leuteritz K, Stuckenberg E, Richter D, Stöbel-Richter Y, Lordick F, Geue K (2021). Psychosocial aftercare of adolescent and young adult cancer survivors in Germany: Awareness, utilisation, satisfaction and associated factors. Psychooncology, 30(8), 1311-1321.
     
  155. Scarpitta A, Hacker UT, Büning H, Boyer O, Adriouch S (2021). Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses. Front Oncol, 11(), 731598.
     
  156. Wuerstlein R, Harbeck N, Grischke EM, Forstmeyer D, von Schumann R, Krabisch P, Lüdtke-Heckenkamp K, Stefek A, Stoetzer O, Grafe A, Kaltenecker G, Forstbauer H, Augustin D, Schrader I, Tio J, Nitz U, Gluz O, Kates RE, Graeser MK (2021). Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. Breast Care (Basel), 16(1), 50-58.
     
  157. Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M (2021). Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers, 7(1), 91.
     
  158. Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K (2021). Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol, 18(8), 473-487.
     
  159. Shen J, Kong M, Yang H, Jin K, Chen Y, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Zhang X, Li Q, Wang G, Mao T, Guo X, Lin T, Liu M, Ma D, Ye M, Wang C, Wang Z, Brunelli A, Cerfolio RJ, D'Journo XB, Fernando HC, Lordick F, Fu J, Chen B, Zhu C (2021). Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010). Ann Transl Med, 9(20), 1516.
     
  160. Franck C, Zimmermann N, Goni E, Lippert H, Ridwelski K, Kruschewski M, Kreuser N, Lingohr P, Schildberg C, Vassos N, Waidmann O, Peitz U, Lang H, Grmminger PP, Bruns C, Veits L, Vieth M, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M (2021). Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer. J Gastrointestin Liver Dis, 30(4), 431-437.
     
  161. Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC (2021). Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer, (), 881.
     
  162. Rhode P, Mehdorn M, Lyros O, Kahlert C, Kurth T, Venus T, Schierle K, Estrela-Lopis I, Jansen-Winkeln B, Lordick F, Gockel I, Thieme R (2021). Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. Cancers (Basel), 13(23), 5975.
     
  163. Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, Vernerey D, Oki E, Georgoulias V, Ben-Aharon I, Shi Q (2021). Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. J Clin Oncol, 39(36), 4009-4019.
     
  164. Kuon J, Blasi M, Unsöld L, Vogt J, Mehnert A, Alt-Epping B, van Oorschot B, Sistermanns J, Ahlborn M, Ritterbusch U, Stevens S, Kahl C, Ruellan A, Matthias K, Kubin T, Stahlhut K, Heider A, Lordick F, Thomas M (2021). Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study. Support Care Cancer, (), 520-521.
     
  165. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC (2021). Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, (), 1-13.
     
  166. Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2021). Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer, (), 224-227.
     
  167. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2021). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, (), 1-5.
     
  168. Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, Dhaene K, Wiechen K, Huber C, Maurus D, Arozullah A, Park JW, Schuler M, Al-Batran SE (2021). FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol, 32(5), 609-619.
     
  169. Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, IJzerman M, Solomon BJ (2021). Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. ESMO Open, 6(5), 100224.
     
  170. Franck C, Zimmermann N, Goni E, Lippert H, Ridwelski K, Kruschewski M, Kreuser N, Lingohr P, Schildberg C, Vassos N, Waidmann O, Peitz U, Lang H, Grmminger PP, Bruns C, Veits L, Vieth M, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M (2021). Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer. J Gastrointestin Liver Dis, 30(4), 431-437.
     
  171. Lordick F, Schneider PM (2021). Ösophagus-Karzinom - Neoadjuvante Therapie In: Hölscher AH, Mönig SP, Meyer HJ, Oberer Gastrointestinaltrakt (S. 212-216), Stuttgart: Georg-Thieme-Verlag KG.
     
  172. Lordick F, Haustermanns K (2021). Gastrointestinal Tract Tumors In: Cervantes Andres, Essentials for Clinicians 2nd Edition (S. 23-29), Madrid: Oncology Pro.
     


    173. 2020


  173. Lordick F (2020). Hepatocellular carcinoma-united forces against a global killer. Ann Oncol, 31(4), 449-450.
     
  174. Smyth E, Knodler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F (2020). VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol, 9, 1320-.
     
  175. Lordick F (2020). Chemotherapy for resectable microsatellite instability-high gastric cancer? Lancet Oncol, 21(2), 203-.
     
  176. Lordick F, Herrmann K (2020). Metabolic response assessment and PET-guided treatment of esophageal cancer. Ann Oncol, 31(2), 163-164.
     
  177. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F (2020). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle, 11(1), 135-144.
     
  178. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020). Gastric cancer. Lancet, 396(10251), 635-648.
     
  179. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G (2020). Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol, 31(10), 1320-1335.
     
  180. Lordick F, Ghadimi M, Gockel I, Graeven U, Westphalen CB (2020). Precision Medicine. Visc Med, 36(5), 407-410.
     
  181. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020). Gastric cancer. Lancet, 396(10251), 635-648.
     
  182. Lordick F, Ghadimi M, Gockel I, Graeven U, Westphalen CB (2020). Precision Medicine. Visc Med, 36(5), 407-410.
     
  183. Gockel I, Lordick F (2020). [Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?] Chirurg, 91(5), 384-390.
     
  184. Serra O, Smyth EC, Lordick F (2020). Progress and challenges in gastroesophageal cancer. Curr Probl Cancer, 44(6), 100590.
     
  185. Hacker UT, Bentler M, Kaniowska D, Morgan M, Büning H (2020). Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives. Cancers (Basel), 12(7), 12.
     
  186. Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F (2020). ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 5(Suppl 3), 826-826.
     
  187. Catanese S, Pentheroudakis G, Douillard JY, Lordick F (2020). ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open, 5(Suppl 3), 804-804.
     
  188. Ben-Aharon I, Goshen-Lago T, Turgeman I, Fontana E, Smyth E, Lordick F (2020). Young patients with cancer and a digital social network: the voice beyond the clinic. ESMO Open, 5(3), 651-652.
     
  189. Jenke R, Holzhäuser-Rein M, Mueller-Wilke S, Lordick F, Aigner A, Büch T (2020). SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. Int J Mol Sci, 22(1), 82-83.
     
  190. Schorling RM, Pfrepper C, Golombek T, Cella CA, Muñoz-Unceta N, Siegemund R, Engel C, Petros S, Lordick F, Knödler M (2020). Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients. Oncol Res Treat, 43(9), 414-427.
     
  191. Lordick F, Hacker U, Gockel I, Bläker H (2020). Magenkarzinom. Neue molekulare Konzepte. Deutsches Ärzteblatt, 2, 4-6.
     
  192. Hacker UT (2020). Kachexie bei Tumorerkrankungen TumorDiagnostik & Therapie, 41, 89-92.
     
  193. Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F (2020). ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 5(Suppl 3), 826.
     
  194. Catanese S, Lordick F (2020). Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind? Ann Transl Med, 8(24), 1701.
     
  195. Weise F, Vieth M, Reinhold D, Haybaeck J, Goni E, Lippert H, Ridwelski K, Lingohr P, Schildberg C, Vassos N, Kruschewski M, Krasniuk I, Grimminger PP, Waidmann O, Peitz U, Veits L, Kreuser N, Lang H, Bruns C, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M (2020). Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research. United European Gastroenterol J, 8(2), 175-184.
     
  196. Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2020). [Erratum to: Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 91(4), 318-.
     
  197. Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A, Hagen V, Gleiber W, Bohnet S, Kruggel L, Dille S, Nusch A, Dorfel S, Decker T, Janicke M (2020). Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer. JAMA Netw Open, 3(3), 1-13.
     
  198. Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, Hofheinz RD, Al-Batran SE, Vogel A, Mueller L, Lutz MP, Lordick F, Alsina M, Borchert K, Greil R, Eisterer W, Schad A, Slotta-Huspenina J, Van Cutsem E, Lorenzen S (2020). Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol, 31(2), 228-235.
     
  199. Wagner AD, Lordick F, Grabsch HI, Terashima M, Terada M, Yoshikawa T, Boku N, Kataoka K, Smyth EC, Mauer M, Haustermans K, Moehler MH (2020). Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. Eur J Cancer, 124, 67-76.
     
  200. Le B, Knoedler M, Roberge G (2020). Intraprostatic injection of tranexamic acid to control refractory bleeding while maintaining therapeutic anticoagulation. Urol Case Rep, 28, 100914-.
     
  201. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F (2020). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle, 11(1), 135-144.
     
  202. Lorenzen S, Lordick F, Loosen SH, Tacke F, Trautwein C, Roderburg C, Ettrich TJ, Perkhofer L, Reinacher-Schick A, Stein A (2020). Current status of immunotherapy in gastrointestinal malignancies. Z Gastroenterol, 58(6), 542-555.
     
  203. Götze H, Friedrich M, Taubenheim S, Dietz A, Lordick F, Mehnert A (2020). Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Support Care Cancer, 28(1), 211-220.
     
  204. Prade VM, Kunzke T, Feuchtinger A, Rohm M, Luber B, Lordick F, Buck A, Walch A (2020). De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry. Mol Metab, 36(), 100953.
     
  205. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G (2020). Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol, 31(10), 1320-1335.
     
  206. Lorenzen S, Lordick F, Loosen SH, Tacke F, Trautwein C, Roderburg C, Ettrich TJ, Perkhofer L, Reinacher-Schick A, Stein A (2020). Current status of immunotherapy in gastrointestinal malignancies. Z Gastroenterol, 58(6), 542-555.
     
  207. Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2020). [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 91(4), 319-328.
     
  208. Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, IJzerman M, Solomon B (2020). Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 5(6), 109.
     
  209. Jenke R, Holzhäuser-Rein M, Mueller-Wilke S, Lordick F, Aigner A, Büch T (2020). SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. Int J Mol Sci, 22(1), 82.
     
  210. Schaudinn A, Hudak A, Linder N, Reinhardt M, Stocker G, Lordick F, Denecke T, Busse H (2020). Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data. Obesity (Silver Spring), (), 25.
     
  211. Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP (2020). Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol, 38(35), 4138-4148.
     
  212. Roy AC, Shapiro J, Burge M, Karapetis CS, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T (2020). Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, 20(4), 305-324.
     
  213. Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M (2020). Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology, 9(1), 180-182.
     
  214. Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2020). Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer, 135(), 1-7.
     
  215. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 396(10265), 1817-1828.
     
  216. Schopow N, Kallendrusch S, Gong S, Rapp F, Körfer J, Gericke M, Spindler N, Josten C, Langer S, Bechmann I (2020). Examination of ex-vivo viability of human adipose tissue slice culture. PLoS One, 15(5), 22-27.
     
  217. Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, I Jzerman M, Solomon B (2020). Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 5(6), 1090.
     


    218. 2019


  218. Lordick F (2019). [Vitamin D and omega-3 fatty acid supplementation does not reduce the cancer and cardiovascular risk]. Strahlenther Onkol, 195, 693-694.
     
  219. Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F (2019). High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer, 116, 107-113.
     
  220. Ben-Aharon I, Goshen-Lago T, Fontana E, Smyth E, Guren M, Caballero C, Lordick F (2019). Social networks for young patients with cancer: the time for system agility. Lancet Oncol, 20(6), 765.
     
  221. Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F (2019). EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 19(1), 494.
     
  222. Lordick F, Obermannova R, Vola D, Douillard JY, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes A (2019). Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. ESMO Open, 4(3), e000533-.
     
  223. Fries H, Hitzschke M, Lordick F (2019). A Different Kind of Relapse: Ethanol as an Additive in Chemotherapy Formulations. Oncol Res Treat, 42(6), 350-353.
     
  224. Golombek T, Henker R, Rehak M, Quaschling U, Lordick F, Knodler M (2019). A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. Oncol Res Treat, 42, 123-127.
     
  225. Kotzerke D, Moritz F, Mantovani L, Hambsch P, Hering K, Kuhnt T, Yahiaoui-Doktor M, Forstmeyer D, Lordick F, Knodler M (2019). The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. J Geriatr Oncol, 10, 937-943.
     
  226. Lordick F, Platzbecker U, Büch E, Köhl U (2019). Molekulare und zellbasierte Krebstherapie ? Quo vadis? Onkologe, 25, 61-67.
     
  227. Lordick F (2019). Adenokarzinome des ösophagogastralen Übergangs Onkologe, 25, 1046-1049.
     
  228. Lordick F, Gockel I (2019). Multimodale Therapie bei Adenokarzinomen des ösophagogastralen Übergangs. Onkologe, 25, 1086-1094.
     
  229. Smyth EC, Lordick F (2019). Nivolumab for previously treated squamous oesophageal carcinoma. Lancet Oncol, 20, 1468-1469.
     
  230. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F (2019). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle, 0000, 0000.
     
  231. Lorenzen S, Stahl M, Hofheinz RD, Al-Batran SE, Lordick F (2019). Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncol Res Treat, 000, 1-6.
     
  232. Gotze H, Kohler N, Taubenheim S, Lordick F, Mehnert A (2019). Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol, 10, 55-59.
     
  233. Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Mohler M, Monig S, Obermannova R, Piessen G, Riddell A, Rocken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F (2019). The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer, 112, 1-8.
     
  234. Kuba K, Esser P, Mehnert A, Hinz A, Johansen C, Lordick F, Gotze H (2019). Risk for depression and anxiety in long-term survivors of hematologic cancer. Health Psychol, 38(3), 187-195.
     
  235. Zeynalova N, Schimpf S, Setter C, Yahiaoui-Doktor M, Zeynalova S, Lordick F, Loeffler M, Hinz A (2019). The association between an anxiety disorder and cancer in medical history. J Affect Disord, 246, 640-642.
     
  236. van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM (2019). SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel), 11(2), 187.
     
  237. Jansen-Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, Lordick F, Remane Y, Frontini R, Gockel I (2019). [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. Chirurg, 90(2), 137-145.
     
  238. De Mello RA, Lordick F, Muro K, Janjigian YY (2019). Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. Am Soc Clin Oncol Educ Book, 39, 237-247.
     
  239. Selby P, Popescu R, Lawler M, Butcher H, Costa A (2019). The Value and Future Developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book, 39, 332-340.
     
  240. Golombek T, Henker R, Rehak M, Quaschling U, Lordick F, Knodler M (2019). A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. Oncol Res Treat, 42(3), 123-127.
     
  241. Gotze H, Kohler N, Taubenheim S, Lordick F, Mehnert A (2019). Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol, 10(1), 55-59.
     
  242. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 30(1), 19-33.
     
  243. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 30(1), 34-43.
     
  244. De Mello RA, Lordick F, Muro K, Janjigian YY (2019). Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. Am Soc Clin Oncol Educ Book, 39, 237-247.
     
  245. Shah PH, Leibovich BC, Van Houten H, Lyon TD, Yao X, Knoedler M, Sangaralingham L, Kattah A, Thompson RH, Shah ND, Boorjian SA (2019). Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. J Urol, 202(1), 69-75.
     
  246. Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F (2019). High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer, 116, 107-113.
     
  247. Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Mohler M, Vogel A (2019). Immunotherapy: New Options in Gastrointestinal Cancers? Visc Med, 35(1), 47-51.
     
  248. Gockel I, Lordick F, Lyros O, Kreuser N, Holscher AH, Wittekind C (2019). [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences]. Chirurg, 10, 4731-4742.
     
  249. Hinz A, Herzberg PY, Lordick F, Weis J, Faller H, Brahler E, Harter M, Wegscheider K, Geue K, Mehnert A (2019). Age and gender differences in anxiety and depression in cancer patients compared with the general population. Eur J Cancer Care (Engl), 28, 13129.
     
  250. Kuon J, Vogt J, Mehnert A, Alt-Epping B, van Oorschot B, Sistermanns J, Ahlborn M, Ritterbusch U, Stevens S, Kahl C, Ruellan A, Matthias K, Kubin T, Stahlhut K, Heider A, Lordick F, Thomas M (2019). Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment. Oncol Res Treat, 42, 650-659.
     
  251. Tureci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol, 30, 1487-1495.
     
  252. Gotze H, Taubenheim S, Dietz A, Lordick F, Mehnert-Theuerkauf A (2019). Fear of cancer recurrence across the survivorship trajectory: Results from a survey of adult long-term cancer survivors. Psychooncology, 28, 2033-2041.
     
  253. Moehler M, Al-Batran SE, Andus T, Arends J, Arnold D, Baretton G, Bornschein J, Budach W, Daum S, Dietrich C, Ebert M, Fischbach W, Flentje M, Gockel I, Grenacher L, Haier J, Hocht S, Jakobs R, Jenssen C, Kade B, Kanzler S, Langhorst J, Link H, Lordick F, Lorenz D, Lorenzen S, Lutz M, Messmann H, Meyer HJ, Monig S, Ott K, Quante M, Rocken C, Schlattmann P, Schmiegel WH, Schreyer A, Tannapfel A, Thuss-Patience P, Weimann A, Unverzagt S (2019). S3-Leitlinie Magenkarzinom ? Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs Z Gastroenterol, 57, 1517-1632.
     
  254. Gockel I, Jansen-Winkeln B, Haase L, Niebisch S, Moulla Y, Lyros O, Lordick F, Schierle K, Wittekind C, Thieme R (2019). Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori, 0000, 0000.
     
  255. Lehmann-Laue A, Ernst J, Mehnert A, Taubenheim S, Lordick F, Gotze H (2019). [Supportive Care and Information Needs of Cancer Survivors: A Comparison of Two Cohorts of Longterm Cancers Survivors 5 and 10 Years after Primary Cancer Diagnosis]. Psychother Psychosom Med Psychol, 0000, 0000.
     
  256. Moulla Y, Petersen TO, Maiwald B, Balis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2019). [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 0000, 0000.
     
  257. Lorenzen S, Stahl M, Hofheinz RD, Al-Batran SE, Lordick F (2019). Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncol Res Treat, 0000, 1-6.
     
  258. Gockel I, Lordick F, Lyros O, Kreuser N, Holscher AH, Wittekind C (2019). [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences]. Chirurg, 0000, 0000.
     
  259. Meier C, Taubenheim S, Lordick F, Mehnert-Theuerkauf A, Gotze H (2019). Depression and anxiety in older patients with hematological cancer (70+) - Geriatric, social, cancer- and treatment-related associations. J Geriatr Oncol, 0000, 0000.
     
  260. Zhang L, Rossi A, Lange L, Meumann N, Koitzsch U, Christie K, Nesbit MA, Moore CBT, Hacker UT, Morgan M, Hoffmann D, Zengel J, Carette JE, Schambach A, Salvetti A, Odenthal M, Buning H (2019). Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells. Hum Gene Ther, 30, 1284-1296.
     
  261. Klapdor R, Wang S, Morgan M, Dork T, Hacker U, Hillemanns P, Buning H, Schambach A (2019). Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. Int J Mol Sci, 20, 0000.
     
  262. Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Mohler M, Vogel A (2019). Immunotherapy: New Options in Gastrointestinal Cancers? Visc Med, 35, 47-51.
     
  263. Prill S, Rebstock J, Tennemann A, Korfer J, Sonnichsen R, Thieme R, Gockel I, Lyros O, Monecke A, Wittekind C, Weimann A, Grosser K, Wiechmann V, Kubick C, Bechmann I, Lordick F, Kallendrusch S (2019). Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer. Oncotarget, 10(46), 4731-4742.
     
  264. Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F (2019). High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer, 116, 107-113.
     
  265. Klinghammer K, Gauler T, Dietz A, Grunwald V, Stohlmacher J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Grosse-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U (2019). Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). Eur J Cancer, 122, 53-60.
     
  266. Ranacher C, Consani C, Tortschanoff A, Rauter L, Holzmann D, Fleury C, Stocker G, Fant A, Schaunig H, Irsigler P, Grille T, Jakoby B (2019). A CMOS Compatible Pyroelectric Mid-Infrared Detector Based on Aluminium Nitride. Sensors (Basel), 19(11), 1-10.
     
  267. Kotzerke D, Moritz F, Mantovani L, Hambsch P, Hering K, Kuhnt T, Yahiaoui-Doktor M, Forstmeyer D, Lordick F, Knodler M (2019). The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. J Geriatr Oncol, 10(6), 937-943.
     
  268. Richter D, Mehnert A, Forstmeyer D, Ernst J, Geue K (2019). Health Literacy in Adolescent and Young Adult Cancer Patients and Its Association with Health Outcomes. J Adolesc Young Adult Oncol, 8(4), 451-457.
     
  269. Pech O, Lordick F (2019). Ösophaguskarzinom In: Riemann JF, Fischbach W, Galle PR, Mössner J , Referenz Gastroenterologie (S. 295-301), Stuttgart: Georg Thieme Verlag.
     
  270. Lordick F (2019). Chemotherapie In: Riemann JF, Fischbach W, Galle PR, Mössner J, Referenz Gastroenterologie (S. 1000-1006), Stuttgart: Georg Thieme Verlag .
     


    271. 2018


  271. Lordick F, Smyth EC (2018). Two steps forward and one step back. Nat Rev Clin Oncol, 0000, 0000.
     
  272. Lordick F, Röcken C (2018). Molekulares Tumorboard. Magenkarzinom. Prädiktoren der Immuntherapie Forum, 6, 405-410.
     
  273. Lordick F (2018). Towards risk-adapted perioperative treatment of gastroesophageal cancer. Ann Oncol, 0000, 0000.
     
  274. Lordick F, Röcken C (2018). Molekulares Tumorboard. Magenkarzinom. Prädiktoren der Immuntherapie Forum, 0000, 12312-018-0501-5 .
     
  275. Ilson D, Lordick F (2018). Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer? Lancet Oncol, 19, 1285-1286.
     
  276. Lordick F (2018). More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. Eur J Cancer, 97, 25-26.
     
  277. Adenis A, Lordick F (2018). Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. JAMA Oncol, 4, 887-888.
     
  278. Lordick F (2018). Response-adapted treatment stratification in oesophago-gastric cancer Eur J Cancer, 92, 3.
     
  279. Lordick F (2018). Changing paradigms in adjuvant treatment of colorectal cancer. Lancet Gastroenterol Hepatol, 3, 6-8.
     
  280. Stocker G, Hacker UT, Fiteni F, John Mahachie J, Roth AD, Van Cutsem E, Peeters M, Lordick F, Mauer M (2018). Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. Eur J Cancer, 99, 49-57.
     
  281. Knodler M, Korfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F (2018). Randomised phase II trial to investigate catumaxomab (anti-EpCAM?×?anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer, 119, 296-302.
     
  282. Lordick F (2018). Changing paradigms in adjuvant treatment of colorectal cancer. Lancet Gastroenterol Hepatol, 3(1), 6-8.
     
  283. Knoedler MA, Jeffery MM, Philpot LM, Meier S, Almasri J, Shah ND, Borah BJ, Murad MH, Larson AN, Ebbert JO (2018). Risk Factors Associated With Health Care Utilization and Costs of Patients Undergoing Lower Extremity Joint Replacement. Mayo Clin Proc Innov Qual Outcomes, 2(3), 248-256.
     
  284. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S (2018). Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl), 27(1), 12645.
     
  285. Pfirrmann D, Simon P, Mehdorn M, Hansig M, Stehr S, Selig L, Weimann A, Knodler M, Lordick F, Mehnert A, Gockel I (2018). [Preconditioning prior to visceral oncological surgery : A paradigm shift in visceral surgery?] Chirurg, 89, 896-902.
     
  286. Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kolbl O, Hautmann MG, Strutz J, Schreiber F, Bockmuhl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehulsing M, Schroeder U, Woll (2018). Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol, 29, 2105-2114.
     
  287. Sonnichsen R, Hennig L, Blaschke V, Winter K, Korfer J, Hahnel S, Monecke A, Wittekind C, Jansen-Winkeln B, Thieme R, Gockel I, Grosser K, Weimann A, Kubick C, Wiechmann V, Aigner A, Bechmann I, Lordi (2018). Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clin Colorectal Cancer, 17, 189-199.
     
  288. Urban C, Buck A, Siveke JT, Lordick F, Luber B, Walch A, Aichler M (2018). PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. Biochim Biophys Acta Gen Subj, 1862, 51-60.
     
  289. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S (2018). Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl), 27(1), 0.
     
  290. Stahl M, Maderer A, Lordick F, Mihaljevic AL, Kanzler S, Hoehler T, Thuss-Patience P, Monig S, Kunzmann V, Schroll S, Sandermann A, Tannapfel A, Meyer HJ, Schuhmacher C, Wilke H, Moehler M (2018). Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). Eur J Cancer, 93, 119-126.
     
  291. Lelorain S, Cattan S, Lordick F, Mehnert A, Mariette C, Christophe V, Cortot A (2018). In which context is physician empathy associated with cancer patient quality of life? Patient Educ Couns, 101, 1216-1222.
     
  292. Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S (2018). Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. Eur J Cancer, 90, 26-33.
     
  293. Polom K, Boger C, Smyth E, Marrelli D, Behrens HM, Marano L, Becker T, Lordick F, Rocken C, Roviello F (2018). Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. Eur J Surg Oncol, 44, 626-631.
     
  294. Berger AK, Lucke S, Abel U, Haag GM, Grullich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jager D (2018). Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. Br J Cancer, 119, 170-175.
     
  295. Esser P, Kuba K, Mehnert A, Johansen C, Hinz A, Lordick F, Gotze H (2018). Quality of life in survivors of hematological malignancies stratified by cancer type, time since diagnosis and stem cell transplantation. Eur J Haematol, 101, 340-348.
     
  296. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli (2018). Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol, 36, 2796-2803.
     
  297. Gotze H, Taubenheim S, Dietz A, Lordick F, Mehnert A (2018). Comorbid conditions and health-related quality of life in long-term cancer survivors-associations with demographic and medical characteristics. J Cancer Surviv, 12, 712-720.
     
  298. Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Hoblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Weise K, Schuller V, (2018). Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level. Cancer Med, 7, 5057-5065.
     
  299. Gotze H, Kohler N, Taubenheim S, Lordick F, Mehnert A (2018). Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol, 18, 1879-4062.
     
  300. Jansen-Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, Lordick F, Remane Y, Frontini R, Gockel I (2018). [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. Chirurg, 00000, 00104-018-0667-5.
     
  301. Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, Braga M, Caballero C, Carneiro F, Cassinello F, Dekker JW, Delgado-Bolton R, Haustermans K, Henning G, Hutter B, Lovey J, Netikova (2018). ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Crit Rev Oncol Hematol, 122, 179-193.
     
  302. Rinke A, Wiedenmann B, Auernhammer C1, Bartenstein P2, Bartsch DK3, Begum N4, Faiss S5, Fottner C6, Gebauer B7, Goretzki P8, Lynen Jansen P9, Pöpperl G10, Scherübl H11, Weber MM6, Gress TM, Pavel M, A (2018). [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Z Gastroenterol, 56, 583-681.
     
  303. Aggelis V, Cunningham D, Lordick F, Smyth EC (2018). Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. Ann Oncol, 29, 1377-1385.
     
  304. Piegeler T, Stehr SN, Pfirrmann D, Knodler M, Lordick F, Mehnert A, Selig L, Weimann A, Mehdorn M, Gockel I, Simon P (2018). [Special situations of preconditioning and prehabilitation in oncological visceral surgery]. Chirurg, 89, 903-908.
     
  305. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yosh (2018). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 0000, 0000.
     
  306. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino (2018). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 0000, 0000.
     
  307. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bha (2018). Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol, 0000, 0000.
     
  308. Gockel I, Jansen-Winkeln B, Haase L, Rhode P, Mehdorn M, Niebisch S, Moulla Y, Lyros O, Lordick F, Schierle K, Wittekind C, Thieme R (2018). Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. J Gastric Cancer, 0000, 379-391.
     
  309. Zeynalova N, Schimpf S, Setter C, Yahiaoui-Doktor M, Zeynalova S, Lordick F, Loeffler M, Hinz A (2018). The association between an anxiety disorder and cancer in medical history. J Affect Disord, 246, 640-642.
     
  310. Lobe M, Staubert S, Goldberg C, Haffner I, Winter A (2018). Towards Phenotyping of Clinical Trial Eligibility Criteria. Stud Health Technol Inform, 248, 293-299.
     
  311. Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, Haffner I, Schierle K, Weirich G, Luber B (2018). Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol Oncol, 12(4), 441-462.
     
  312. Maciolek KA, Best SL, Lopez V, Posielski N, Knoedler M, Bushman WA, Jarrard DF, Downs TM, Abel EJ, Richards KA (2018). Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol, 36(8), 363-363.
     
  313. S von Haeling, J Arends, D Blum, and U Hacker (2018). Kachexie bei Tumorerkrankungen. In: Hacker U, Erkennen und multimodal behandeln. (S. 20-28), München: Springer.
     
  314. Golombek T, Lordick F (2018). Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung In: B Rau, P Piso, A Königsrainer, Peritoneale Tumoren und Metastasen (S. 245-260), Deutschland: Springer Verlag GmbH Deutschland .
     
  315. Lordick F, Gockel I, Mössner J (2018). Ösophaguskarzinom beim alten und geriatrischen Patienten In: Ebert M, Härtel N, Wedding U, Geriatrische Onkologie (S. 313-324), Deutschland: Springer Nature .
     
  316. Lordick F (2018). Immunonkologie der soliden Tumoren ? Neues In: Petrasch S, Ehninger G., Colloquium Onkologie 24. Update Hämatologie / Onkologie 2017 (S. 31-40), München: Lukon Verlag.
     


    317. 2017


  317. Hacker U (2017). Krebstherapie und Tumoransprechen. Forum, 32(3), 230-235.
     
  318. Lordick F, Hacker U (2017). Gewichtsverlust aus onkologischer Sicht. Aktuelle Ernaehrungsmedizin, 42(2), 115-122.
     
  319. Mehnert A, Lordick F (2017). [Cancer Throughout the Lifespan - Addressing the Psychosocial Needs of Diverse Populations]. Psychother Psychosom Med Psychol, 67(7), 277-278.
     
  320. Lordick F (2017). Treatment of oesophageal cancer - Stressing the patient perspective. Editorial. Eur J Cancer, 84, 360-362.
     
  321. Kataoka K, Deleersnijder A, Lordick F (2017). Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? Eur J Surg Oncol, 43(10), 1835-1845.
     
  322. Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, Lordick F (2017). Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer, 20(5), 904-912.
     
  323. Lordick F, Shitara K, Janjigian YY (2017). New agents on the horizon in gastric cancer. Ann Oncol, 28(8), 1767-1775.
     
  324. Haag GM, Stocker G, Quidde J, Jaeger D, Lordick F (2017). Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study. BMC Cancer, 17(1), 509.
     
  325. Obermannova R, Lordick F (2017). Management of Metastatic Gastric Cancer. Hematol Oncol Clin North Am, 31(3), 469-483.
     
  326. Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Mohler M, Quaas A, Rocken C, Ruschoff J, Tannapfel A, Thuss-Patience P, Baretton G (2017). HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol, 143(5), 835-841.
     
  327. Lordick F, Mossner J (2017). [Current Standard Diagnosis and Treatment of Colon Cancer]. Dtsch Med Wochenschr, 142(7), 487-490.
     
  328. Lordick F (2017). Salvage chemotherapy for advanced gastric cancer: more than a false hope? Lancet Gastroenterol Hepatol, 2(4), 240-241.
     
  329. Lordick F (2017). Anti-angiogenesis: disappointment in localised oesophagogastric cancer. Lancet Oncol, 18(3), 278-279.
     
  330. Lordick F (2017). [Novel pharmaceutical treatment approaches for gastric cancer]. Pathologe, 38(2), 87-92.
     
  331. Sonnichsen R, Hennig L, Blaschke V, Winter K, Korfer J, Hahnel S, Monecke A, Wittekind C, Jansen-Winkeln B, Thieme R, Gockel I, Grosser K, Weimann A, Kubick C, Wiechmann V, Aigner A, Bechmann I, Lordick F, Kallendrusch S (2017). Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clin Colorectal Cancer, 00, 00.
     
  332. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S (2017). Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist, 22(5), 601-608.
     
  333. Klapdor R, Wang S, Hacker U, Buning H, Morgan M, Dork T, Hillemanns P, Schambach A (2017). Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. Hum Gene Ther, 28(10), 886-896.
     
  334. Blank V, Schierle K, Hacker U, Herta T, Vucinic V, Hoffmeister A, Mossner J, Jansen-Winkeln B, Keim V, Karlas T (2017). An unusual hypoechoic solid mass in the pancreatic head. Z Gastroenterol, 55(4), 375-378.
     
  335. Hosel M, Huber A, Bohlen S, Lucifora J, Ronzitti G, Puzzo F, Boisgerault F, Hacker UT, Kwanten WJ, Kloting N, Bluher M, Gluschko A, Schramm M, Utermohlen O, Bloch W, Mingozzi F, Krut O, Buning H (2017). Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors. Hepatology, 66(1), 252-265.
     
  336. Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O (2017). A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer, 116(5), 600-608.
     
  337. Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ (2017). Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, 17(10), 951-964.
     
  338. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G (2017). TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol, 24(8), 2252-2258.
     
  339. Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D (2017). Oesophageal cancer. Nat Rev Dis Primers, 3, 17048.
     
  340. Kunzke T, Balluff B, Feuchtinger A, Buck A, Langer R, Luber B, Lordick F, Zitzelsberger H, Aichler M, Walch A (2017). Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. Oncotarget, 8(40), 68012-68025.
     
  341. Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M (2017). What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol, 28(7), 1473-1483.
     
  342. Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Buchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos (2017). 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer, 79, 41-49.
     
  343. Pfirrmann D, Tug S, Brosteanu O, Mehdorn M, Busse M, Grimminger PP, Lordick F, Glatz T, Hoeppner J, Lang H, Simon P, Gockel I (2017). Internet-based perioperative exercise program in patients with Barretts carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial. BMC Cancer, 17(1), 413.
     
  344. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D (2017). Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol, 3(5), 620-627.
     
  345. Keck Chair T, Herrlinger Chair KR, Faiss S, Lordick F, Mansky T, Welsch T (2017). Arguments for and against Centralization in Oncologic Visceral Medicine. Visc Med, 33(2), 148-152.
     
  346. Klar E, Buchler MW, Lang H, Lordick F, Mittler J, Mizuno T, Torzilli G, Ulrich A, Vauthey JN (2017). Oligometastases of Gastrointestinal Cancer Origin. Visc Med, 33(1), 76-81.
     
  347. Kallendrusch S, Körfer J, Lordick F, Bechmann I (2017). Human tumor slice cultures for cancer research and drug testing. Integr Cancer Sci Therap, 4(4), 1000251.
     
  348. Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hanel M, Salwender HJ, Weisel K, Durig J, Gorner M, Kirchner H, Peter N, Graeven U, Lor (2017). Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone Marrow Transplant, 52(8), 1194-1198.
     
  349. Keilholz U, Rohde L, Mehlitz P, Knoedler M, Schmittel A, Kummerlen V, Klinghammer K, Treasure P, Lassus M, Steventon G, Machacek M, Utku N (2017). First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. Eur J Cancer, 80, 14-25.
     
  350. Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S (2017). Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. Eur J Cancer, 90, 26-33.
     
  351. Behrens A, Lordick F (2017). Facharztwissen Gastroenterologie. In: Layer P, Rosien U, Magenkarzinom. (S. 134-145), München: Elsevier Verlag.
     
  352. Behrens A, Lordick F (2017). Facharztwissen Gastroenterologie. In: Layer P, Rosien U, Ösophagustumoren. (S. 100-110), München: Elsevier Verlag.
     
  353. Stocker G, Lordick F (2017). Gastroenterologische Infektiologie. In: Lübbert C, Vogelmann R , Infektionen und Entzündungsreaktionen als Folge der Tumorbehandlung. (S. 425-435), Berlin: De Gruyter Verlag.
     
  354. Lordick F, Hacker U (2017). Zielgerichtete Therapie des kolorektalen Karzinoms. In: Hacker U, Zielgerichtete Therapie des kolorektalen Karzinoms. (S. 1-102), Bremen-London-Boston: UniMed Verlag AG.
     
  355. Lorenzen S, Lordick F (2017). Nausea und Emesis in der Onkologie. In: Lordick F, Nausea und Emesis in der Onkologie. (S. 1-160), Bremen-London-Boston: UniMed Verlag AG.
     
  356. Lordick F (2017). Elsevier Essentials Onkologie. In: Alt-Epping B, Fuxius S, Wedding U, Kapitel 16 Onkologische Tumortherapie in 20 Jahren. (S. 141-144), München: Elsevier GmbH.
     
  357. Hacker U, Lordick F (2017). Tumor Angiogenesis. In: D. Marmé, Anti-Angiogenics in Gastroesophageal Cancer. (S. 1-19), Basel: Springer International Publishing AG.
     


    358. 2016


  358. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D (2016). Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 27(Suppl.5), v50-57.
     
  359. Lordick F, Terashima M (2016). Gastric cancer adjuvant therapy. Best Pract Res Clin Gastroenterol, 30(4), 581-591.
     
  360. Lordick F, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Rocken C, Ruschoff J, Tannapfel A (2016). [HER2 testing in gastric cancer - results of a German expert meeting]. Z Gastroenterol, 54(8), 791-796.
     
  361. Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gassler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F (2016). Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med, 5(7), 1444-1453.
     
  362. Obermannova R, Lordick F (2016). Insights into next developments in advanced gastric cancer. Curr Opin Oncol, 28(4), 367-375.
     
  363. Lordick F, Janjigian YY (2016). Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol, 13(6), 348-360.
     
  364. Lordick F, Hacker U (2016). [Weight loss in cancer patients]. Dtsch Med Wochenschr, 141(4), 247-252.
     
  365. Alt-Epping B, Seidel W, Vogt J, Mehnert A, Thomas M, van Oorschot B, Wolff H, Schliephake H, Canis M, Droge LH, Nauck F, Lordick F (2016). Symptoms and Needs of Head and Neck Cancer Patients at Diagnosis of Incurability - Prevalences, Clinical Implications, and Feasibility of a Prospective Longitudinal Multicenter Cohort Study. Oncol Res Treat, 39(4), 186-191.
     
  366. Ochsenreither S, Lordick F (2016). New concepts for clinical trial design in oncology. Forum , 31(3), 221-225.
     
  367. van Oorschot B, Ruellan A, Lordick F (2016). Für die Arbeitsgemeinschaft Palliativmedizin der Deutschen Krebsgesellschaft (APM). Choosing wisely ? Klug entscheiden bei Tumorpatienten mit limitierter Prognose. Forum, 31(3), 237-240.
     
  368. Lorenzen S, Lordick F (2016). Fortgeschrittenes Magenkarzinom Status quo der systemischen Therapie und Einfluss auf die Lebensqualität. Onkologe, 22(6), 406-412.
     
  369. Kallendrusch S, Schopow N, Stadler SC, Buning H, Hacker UT (2016). Adeno-Associated Viral Vectors Transduce Mature Human Adipocytes in Three-Dimensional Slice Cultures. Hum Gene Ther Methods, 27(5), 171-173.
     
  370. Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, Hedge P, Van Cutsem E, Coutelle O, Buning H (2016). Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. Br J Cancer, 114(8), 855-862.
     
  371. Buning H, Hacker UT (2016). Inhibitors of Angiogenesis. Adv Exp Med Biol, 917, 261-285.
     
  372. Hacker U (2016). Das Tumorstroma und seine Bedeutung für die Therapie solider Tumoren. Forum, 31(3), 216-220.
     
  373. Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T (2016). The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis, 48(11), 1283-1289.
     
  374. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F (2016). Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. Eur J Cancer, 68, 208-209.
     
  375. Engelmann D, Scheffold K, Friedrich M, Hartung TJ, Schulz-Kindermann F, Lordick F, Schilling G, Lo C, Rodin G, Mehnert A (2016). Death-Related Anxiety in Patients With Advanced Cancer: Validation of the German Version of the Death and Dying Distress Scale. J Pain Symptom Manage, 52(4), 582-587.
     
  376. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. Eur J Cancer, 63, 11-24.
     
  377. Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Rothling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR (2016). ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 16, 503.
     
  378. Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Rocken C, Ruschoff J, Tannapfel A, Lordick F, Al-Batran S, Hofheinz R, Lorenzen S, Moehler M, Thuss-Patience P (2016). [HER2 testing in gastric cancer : Results of a meeting of German experts]. Pathologe, 37(4), 361-366.
     
  379. Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M (2016). Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur J Cancer, 59, 160-170.
     
  380. Janmaat VT, Bruno MJ, Polinder S, Lorenzen S, Lordick F, Peppelenbosch MP, Spaander MC (2016). Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. PLoS One, 11(4), e0153943.
     
  381. Stadler SC, Hacker U, Burkhardt R (2016). Cholesterol metabolism and breast cancer. Curr Opin Lipidol, 27(2), 200-201.
     
  382. Hofheinz RD, Ronellenfitsch U, Kubicka S, Falcone A, Burkholder I, Hacker UT (2016). Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterol Res Pract, 2016, 9189483.
     
  383. Lordick F (2016). Zielgerichtete medikamentöse Therapie. In: Mehnert A, Koch U, Handbuch Psychoonkologie. (S. 42-52), Göttingen: Holzgreve Verlag GmbH.
     


    384. 2015


  384. Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT (2015). Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalization without inducing empty basement membrane sleeves in xenograft tumors. Br J Cancer, 112(3), 495-503.
     
  385. Hacker UT (2015). Cetuximab oder Bevacizumab in der Erstlinientherapie des metastasierten kolorektalen Karzinoms? Journalclub. Der Onkologe, 21(2), 161-162.
     
  386. Gockel I, Hoffmeister A, Lordick F (2015). [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. Chirurg, 86(11), 1014-1022.
     
  387. Dietz A, Lordick F (2015). Update Skills in Head and Neck Surgery and Oncology 2015 : Aktuelles klinikrelevantes Wissen praxisnah präsentiert. HNO, 63(12), 880-881.
     
  388. Hacker U, Lordick F (2015). [Current standards in the treatment of gastric cancer]. Dtsch Med Wochenschr, 140(16), 1202-1205.
     
  389. Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weissinger F, Schnoy E, Becker K, Stocker G, Ruschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F (2015). Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer, 51(5), 569-576.
     
  390. Lordick F (2015). Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis. Nat Rev Clin Oncol, 12(1), 7-8.
     
  391. Lordick F (2015). [In Process Citation]. Oncol Res Treat, 38(5), 260-263.
     
  392. Lordick F, Gockel I, Wittekind C (2015). Magenkarzinom: Neue molekulare Konzepte. Dtsch Arztebl , 112(20), 10.3238.
     
  393. Behrens A, Ell C, Lordick F (2015). Perioperative and Palliative Chemotherapy for Esophageal Cancer. Viszeralmedizin , 31(5), 341-346.
     
  394. Buning H, Huber A, Zhang L, Meumann N, Hacker U (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol, 24, 94-104.
     
  395. Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, Holscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer HJ, Palmqvist A, Rocken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wi (2015). International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer, 18(3), 550-563.
     
  396. Boehm A, Lindner F, Wichmann G, Bauer U, Wittekind C, Knoedler M, Lordick F, Dietzsch S, Scholz M, Kortmann R, Dietz A (2015). Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol, 272(8), 2017-2025.
     
  397. Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jager D, Buchler M, Bruckner T, Siewert J, Ott K (2015). Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer, 18(2), 314-325.
     
  398. Weihrauch MR, Richly H, von Bergwelt-Baildon MS, Schmidt M, Hacker UT, Alexander Shimabukuro A, Holtick U, Nokay B, Schroff M, Wittig B, Scheulen ME (2015). Phase I clinical study of the TLT9-agonist MGN1703 in patients with metastatic solid tumors. Eur J Cancer, 51(2), 146-156.
     
  399. Dietz A, Loeffler M, Rosolowski M, Kreuz M, Lordick F, Knodler M, Mozet C, Wichmann G (2015). [Gene expression analyses and their possible clinical benefit in head and neck cancer]. HNO, 63(11), 773-785.
     
  400. Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, Ulrich A, Buchler MW, Ott K (2015). Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. Eur J Surg Oncol, 41(10), 1340-1347.
     
  401. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, T (2015). Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res, 21(24), 5469-5479.
     
  402. Scheffold K, Philipp R, Engelmann D, Schulz-Kindermann F, Rosenberger C, Oechsle K, Harter M, Wegscheider K, Lordick F, Lo C, Hales S, Rodin G, Mehnert A (2015). Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial. BMC Cancer, 15, 592.
     
  403. Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R (2015). TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer, 15, 532.
     
  404. Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jager D, Grenacher L, Bruckner T, Buchler MW, Ott K (2015). Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Ann Surg Oncol, 22 (Suppl 3), 905-914.
     
  405. Fakhrian K, Ordu AD, Nieder C, Lordick F, Kup PG, Theisen J, Combs SE, Geinitz H (2015). Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy. Tumori, 101(3), 263-267.
     
  406. Schmidt T, Lordick F, Herrmann K, Ott K (2015). Value of functional imaging by PET in esophageal cancer. J Natl Compr Canc Netw, 13(2), 239-247.
     
  407. Ott K, Lordick F, Siewert JR (2015). Oesophageal Cancer: Treatment Strategies In: , Kuzdzal J. Textbook of Thoracic Surgery, Volume 2 (S. 591-600), Cracow : Medycyna Praktyczna.
     
  408. Bahra M, Lordick F, Lutz M, Glanemann M, Neuhaus P (2015). Pankreaskarzinom In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 557-567), Berlin Heidelberg: Springer.
     
  409. Lordick F (2015). Supportive Tumortherapien. In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 440-445), Berlin Heidelberg: Springer.
     


    410. 2014


  410. Lordick F, Hoffmeister A (2014). [Treatment of gastric cancer.] Internist (Berl), 55(1), 15-22.
     
  411. Lordick F, Lorenzen S, Yamada Y, Ilson D (2014). Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer, 17(2), 213-225.
     
  412. Gomez-Martin C, Lopez-Rios F, Aparicio J, Barriuso J, Garcia-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vazquez-Sequeiros E, Lordick F (2014). A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett, 351(1), 30-40.
     
  413. Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A (2014). Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev, 40(6), 692-700.
     
  414. Lordick F (2014). Mistletoe treatment for cancer-promising or passé? Editorial. Dtsch Arztebl Int, 111(29-30), 491-492.
     
  415. Lorenzen S, Sporl S, Lordick F (2014). [Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer]. Z Gastroenterol, 52(8), 821-830.
     
  416. Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Tredan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F (2014). Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol, 31(8), 76.
     
  417. Lordick F (2014). Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol, 15(9), 914-916.
     
  418. Lordick F, Knodler M, Hacker U, Bartels M (2014). [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy]. Chirurg, 85(1), 11-16.
     
  419. Ahlhorn M, Lordick F (2014). Fortgeschrittenes Pankreaskarzinom. Möglicher Einfluss der Mistel auf das Überleben Der Onkologe, 20, 376-378.
     
  420. Coutelle O, Büning H, Plütschow A, Fuchs M, Escalona-Espinosa L, Engert A, Hacker UT (2014). Prognostic Serum Cytokines in Classical Hodgkin Lymphoma? Letter. Clin Cancer Res, 20(24), 6633.
     
  421. Lordick F, Ricke J, Mohnike K, Hacker U (2014). How to create evidence for the integration of locoregional treatments in future oncological treatment concepts? Viszeralmedizin, 30(4), 261-268.
     
  422. Coutelle O, Hornig-Do HT, Witt A, Andree M, Schiffmann LM, Piekarek M, Brinkmann K, Seeger JM, Liwschitz M, Miwa S, Hallek M, Kronke M, Trifunovic A, Eming SA, Wiesner RJ, Hacker UT, Kashkar H (2014). Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing. EMBO Mol Med, 6(5), 624-639.
     
  423. Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Buchler M, Lordick F, Slotta-Huspenina J, Weichert W, Hofler H, Feith M, Ott K (2014). A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. Ann Surg Oncol, 21(3), 915-921.
     
  424. Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, Dietz A, Bechmann I (2014). Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer, 110(2), 479-488.
     
  425. Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, Siewert JR, Ott K (2014). Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer, 17(3), 478-88.
     
  426. Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R (2014). Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol, 38(11), 1551-1556.
     
  427. Aichler M, Luber B, Lordick F, Walch A (2014). Proteomic and metabolic prediction of response to therapy in gastric cancer. World J Gastroenterol, 20(38), 13648-13657.
     
  428. Fakhrian K, Ordu AD, Haller B, Theisen J, Lordick F, Bisof V, Molls M, Geinitz H (2014). Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus : A comparison of two preoperative radiochemotherapy regimens. Strahlenther Onkol, 190(11), 987-992.
     
  429. Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A (2014). Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget, 5(16), 6620-6632.
     
  430. Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Tureci O (2014). Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. Cancer Immunol Immunother, 63(12), 1273-1284.
     
  431. Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfeld C, Grenacher L, Siewert JR, Buchler M, Ott K (2014). Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol, 21(5), 1739-1748.
     
  432. Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthun T, Langer R, Buchler MW, Siewert JR, Lordick F, Ott K (2014). Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer, 110(7), 1712-1720.
     
  433. Homayounfar K, Bleckmann A, Helms HJ, Lordick F, Ruschoff J, Conradi LC, Sprenger T, Ghadimi M, Liersch T (2014). Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases. Br J Surg, 101(5), 550-557.
     
  434. Brucher BL, Lyman G, van Hillegersberg R, Pollock RE, Lordick F, Yang HK, Ushijima T, Yeoh KG, Skricka T, Polkowski W, Wallner G, Verwaal V, Garofalo A, D Ugo D, Roviello F, Steinau HU, et al. (2014). Imagine a world without cancer. BMC Cancer, 14, 186.
     
  435. Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfeld C, Bruckner T, Becker K, Kumar R, Ott K (2014). A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. BMC Cancer, 14, 58.
     
  436. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R (2014). Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol, 25(1), 107-116.
     
  437. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH (2014). Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol, 25(5), 1018-1025.
     
  438. Ott K, Schmidt T, Lordick F, Herrmann K (2014). [Importance of PET in surgery of esophageal cancer]. Chirurg, 85(6), 505-512.
     
  439. Fakhrian K, Ordu AD, Lordick F, Theisen J, Haller B, Omrcen T, Molls M, Nieder C, Geinitz H (2014). Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU : More than 20 years experience at a single institution. Strahlenther Onkol, 190(12), 1133-1140.
     
  440. Dietz A, Knödler M, Lordick F (2014). Primärtherapie der Kopf-Hals-Tumoren. Der Onkologe, 20(2), 144-151.
     
  441. Homayounfar K, Lordick F, Ghadimi M (2014). Qualitätssicherung: Multidisziplinäre Tumorboards - trotz Problemen unverzichtbar. Dtsch Ärztebl, 111(22), A 998−1001.
     
  442. Cella CA, Carlomagno C, Lordick F, Moretto R, De Stefano A, Raimondo L, D Armiento M, Camera L, Guadagno E, Attademo L, Feliciano S, Matano E (2014). Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4. Oncol Res Treat, 37(1-2), 55-58.
     
  443. Sallach J, Di Pasquale G, Larcher F, Niehoff N, Rubsam M, Huber A, Chiorini J, Almarza D, Eming SA, Ulus H, Nishimura S, Hacker UT, Hallek M, Niessen CM, Buning H (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther, 22(5), 929-939.
     
  444. Lordick F (2014). Nausea und Emesis in der Onkologie. 1.Auflage 2014 In: Lorenzen S, Nausea und Emesis in der Onkologie. (S. 1-157), Bremen: Uni-Med Verlag AG.
     


    445. 2013


  445. Lordick F, Holscher AH, Haustermans K, Wittekind C (2013). Multimodal treatment of esophageal cancer. Langenbecks Arch Surg, 398(2), 177-87.
     
  446. Lordick F (2013). [Comments on the statement of the German Society of Pathology (DGP) on clinical studies from a clinical perspective]. Pathologe, 34(5), 476-478.
     
  447. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol, 14(6), 490-499.
     
  448. Oorschot BV, Rades D, Lordick F (2013). Connections are clearly more complexy. Dtsch Arztebl Int, 110(44), 753.
     
  449. Lordick F, Rocken C (2013). The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Editorial. Ann Oncol, 24(5), 1135-1138.
     
  450. Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jager D, Buchler M, Siewert JR, Lordick F (2013). Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbecks Arch Surg, 398(2), 239-249.
     
  451. Lordick F, Forstmeyer D, Ahlborn M, Becker-Schiebe M, Hoffmann W, Schumacher G (2013). Medical Treatment of Peritoneal Carcinomatosis. Vizeralmedizin 2013, 29, 213-219.
     
  452. Lordick F, Jähne J (2013). Evidence-Based Medicine oder Erfahrungsmedizin - Grenzentscheidungen in der Onkologie benötigen den erfahrenen Arzt. Viszeralmedizin, 29, 205-206.
     
  453. Lorenzen S, Lordick F (2013). Therapie des fortgeschrittenen Magenkarzinoms. Onkologe 2013, 84, 389-394.
     
  454. Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT (2013). Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer, 109(6), 1408-1413.
     
  455. Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, Weissinger F, Eberhardt W, Keilholz U (2013). Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology, 84(5), 284-289.
     
  456. Wilke H, Lordick F, Meyer HJ, Stahl M (2013). (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the west. Dig Surg, 30(2), 112-118.
     
  457. Warneke VS, Behrens HM, Haag J, Balschun K, Boger C, Becker T, Ebert MP, Lordick F, Rocken C (2013). Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol, 22(3), 127-137.
     
  458. Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N (2013). Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol, 24(8), 2068-2073.
     
  459. Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Blaker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jager D, Buchler M, Siewert JR, Ott K (2013). A reliable risk score for stage IV esophagogastric cancer. Eur J Surg Oncol, 39(8), 823-830.
     
  460. Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Dux M, Farkas S, Folprecht G, Galle P, Geissler M, Gerken G, Ha (2013). [Diagnosis of and therapy for hepatocellular carcinoma]. Z Gastroenterol, 51(11), 1269-1326.
     
  461. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buys (2013). Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst, 105(21), 1600-1607.
     
  462. Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, Rocken C (2013). Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol, 24(3), 725-733.
     
  463. Harren K, Brandhoff B, Knodler M, Tudzynski B (2013). The High-Affinity Phosphodiesterase BcPde2 Has Impact on Growth, Differentiation and Virulence of the Phytopathogenic Ascomycete Botrytis cinerea. PLoS One, 8(11), e78525.
     
  464. Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, Schull S, Andree M, Coutelle O, Yazdanpanah B, Seeger JM, Klubertz D, Drebber U, Hacker UT, Kronke M, Mauch C, Hoppe T, Kashkar H (2013). Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep, 3(3), 881-891.
     
  465. Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Kohne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB (2013). Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol, 24(6), 1560-1567.
     
  466. Lordick F, Hacker U (2013). Zielgerichtete Therapie des kolorektalen Karzinoms. 1. Auflage 2013. In: Hacker U, Zielgerichtete Therapie des kolorektalen Karzinoms. 1. Auflage 2013. (S. 1-45), Bremen: Uni-Med Verlag AG Bremen.
     


    467. 2012


  467. Lordick F (2012). Gastrointestinal cancer: Salvage chemotherapy in gastric cancer-more than a straw? Nat Rev Clin Oncol, 9(6), 312-313.
     
  468. Lordick F (2012). [Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial]. Strahlenther Onkol, 188(7), 636-637.
     
  469. Lordick F (2012). To resect or not resect in metastatic gastric cancer: that is the question! Gastric Cancer, 15(3), 229-231.
     
  470. Lordick F (2012). Supportive treatment – an integral part of cancer Care. Editorial. Magazine of European Medical Oncology , 5(1), 1-2.
     
  471. Lordick F (2012). Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res, 196, 201-211.
     
  472. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K (2012). Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs, 30(3), 1138-1143.
     
  473. Blank S, Blaker H, Schaible A, Lordick F, Grenacher L, Buechler M, Ott K (2012). Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg, 397(1), 45-55.
     
  474. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Holscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, et al. (2012). Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer, 48(16), 2941-53.
     
  475. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, et al. (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308(2), 147-156.
     
  476. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sulberg H, Wittekind C, Potapov S, Staib L, Hess C, et al. (2012). Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol, 13(7), 679-687.
     
  477. Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jager D, Luntz SP, Englert S, Rossion I, Koch M, Buchler MW, Kieser M, Weitz J (2012). Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS-a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer, 12, e142.
     
  478. Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jager D (2012). A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. BMC Cancer, 12, e108.
     
  479. Grenacher L, Schwarz M, Lordick F, Krause B, Roecken C, Moenig S, Ebert M, Jenssen C, Kauczor HU, Moehler M (2012). [S3 guideline - diagnosis and treatment of gastric carcinoma: relevance for radiologic imaging] Rofo, 184(8), 706-712.
     
  480. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K (2012). Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol, 19(7), 2119-2127.
     
  481. Meyer HJ, Holscher AH, Lordick F, Messmann H, Monig S, Schumacher C, Stahl M, Wilke H, Mohler M (2012). [Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg, 83(1), 31-37.
     
  482. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, Nischt R, Dienes HP, Odenthal M (2012). Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest, 92(7), 978-987.
     
  483. Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, Weihrauch MR, von Bergwelt-Baildon M, Hacker UT (2012). Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest, 30(3), 225-230.
     


    484. 2011


  484. Lordick F (2011). Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol, 7(2), 187-199.
     
  485. Lorenzen S, Lordick F (2011). How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol, 23(4), 396-402.
     
  486. Lordick F, Ott K, Krause BJ (2011). [Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas] Dtsch Med Wochenschr, 136(20), 1061-1066.
     
  487. Lordick F (2011). The role of PET in predicting response to chemotherapy in oesophago-gastric cancer. Acta Gastroenterol Belg, 74(4), 530-535.
     
  488. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hofler H, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F (2011). Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 11, e509.
     
  489. Lordick F, Ott K, Sendler A (2011). [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy] Chirurg, 82(11), 968-973.
     
  490. Lordick F (2011). Current standard and trends in oesophageal cancer. Eur J Cancer, 47 (Suppl 3), S353-354.
     
  491. Lordick F (2011). HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clin Transl Oncol, 13(9), 597-598.
     
  492. Hacker U, Buning H (2011). Optimizing the adeno-associated viral vector system: a brief summary. Ther Deliv, 2(8), 967-970.
     
  493. Hacker UT, Wolf J, Wendtner CM (2011). [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]. Dtsch Med Wochenschr, 136(5), 179-181.
     
  494. Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K (2011). Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol Imaging Biol, 13(1), 178-186.
     
  495. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A (2011). Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol, 22(3), 524-535.
     
  496. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rosler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickho (2011). Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant, 46(8), 1045-1052.
     
  497. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S (2011). Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol, 22(6), 1358-1366.
     
  498. Ott K, Lordick F, Blank S, Buchler M (2011). Gastric cancer: surgery in 2011. Langenbecks Arch Surg, 396(6), 743-758.
     
  499. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R (2011). DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol, 18(9), 2688-2698.
     
  500. Strohlein MA, Lordick F, Ruttinger D, Grutzner KU, Schemanski OC, Jager M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM (2011). Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie, 34(3), 101-108.
     
  501. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Bohle E, Bokemeyer C, Bornschein J, et al. (2011). [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"] Z Gastroenterol, 49(4), 461-531.
     
  502. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, zum Buschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ (2011). Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol, 18(12), 3316-3323.
     
  503. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR (2011). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer, 47(10), 1511-1520.
     
  504. Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, Budach V, Keilholz U (2011). Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 17(15), 5197-5204.
     
  505. zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ (2011). (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med, 52(8), 1189-1196.
     
  506. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jager D, Munter MW (2011). Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer, 11, e266.
     
  507. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang Y (2011). The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol, 22 (Suppl 5), v1-9.
     
  508. Coutelle O, Hallek M, Hacker UT (2011). Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer. memo - Magazine of European Medical Oncology, 4(2), 75-78.
     
  509. Lordick F (2011). Biologie und zielgerichtete Therapie des Magenkarzinoms. In: Lordick F, Biologie und zielgerichtete Therapie des Magenkarzinoms. (S. ), Bremen – London – Boston : Uni-Med Verlag AG .
     
  510. Lordick F, Peschel V (2011). Therapie-induzierte Nausea und Emesis in der Onkologie. In: Lordick F, Peschel V , Therapie-induzierte Nausea und Emesis in der Onkologie. (S. 1-93), Bremen – London – Boston: Uni-Med Verlag AG .
     


    511. 2010


  511. Hacker U, Hallek M, Kubicka S (2010). [Multimodality therapy of colorectal cancer]. Internist (Berl), 51(11), 1366-1373.
     
  512. Hofheinz RD, Al-Batran SE, Ridwelski K, Gorg C, Wehle K, Birth M, Fetscher S, Scheiber H, Lukan N, Lordick F (2010). Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie, 33(10), 512-518.
     
  513. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F, Peschel C (2010). Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer, 102(3), 500-505.
     
  514. Lordick F, Lorenzen S (2010). System therapy of esophageal carcinoma and the value of targeted therapies. Onkologe, 16(5), 515-520.
     
  515. Lordick F, Grenacher L, Rocken C, Ebert M, Moehler M, Schumacher G (2010). [Diagnosis and treatment of gastric cancer]. Dtsch Med Wochenschr, 135(34-35), 1671-82.
     
  516. Lordick F, Ott K, Krause BJ (2010). New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Ann Oncol, 21(Suppl 7), 294-299.
     
  517. Klinghammer K, Knodler M, Schmittel A, Budach V, Keilholz U, Tinhofer I (2010). Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 16(1), 304-310.
     
  518. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT (2010). Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer, 103(9), 1407-1414.
     
  519. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Va (2010). Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol, 28(35), 5210-5218.
     
  520. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, Lordick F, Nekolla SG, Rummeny EJ, Wester HJ, Brix G, Schwaiger M, Beer AJ (2010). Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med, 51(11), 1691-1698.
     
  521. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Ron (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 28(31), 4706-4713.
     
  522. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687-697.
     
  523. Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, Hofler H (2010). High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol, 102(5), 503-508.
     
  524. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K (2010). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther, 48(7), 473-475.
     
  525. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi (2010). Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol, 11(1), 38-47.
     
  526. Friederichs J, von Weyhern CW, Rosenberg R, Doll D, Busch R, Lordick F, Siewert JR, Sarbia M (2010). Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. Langenbecks Arch Surg, 395(4), 373-379.
     
  527. Siewert JR, Lordick F (2010). Praxis der Viszeralchirurgie – Onkologische Chirurgie. In: Siewert JR , Praxis der Viszeralchirurgie – Onkologische Chirurgie. (S. ), Heidelberg Berlin New York: Springer Verlag.
     
  528. Lordick F (2010). Biologisch zielgerichtete Therapie. In: Siewert JR, Lordick F, Praxis der Viszeralchirurgie – Onkologische Chirurgie. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     
  529. Lordick F, Beiglböck A, Jäger D, Siewert JR (2010). Multidisziplinarität im Cancer Center. In: Siewert JR, Lordick F, Praxis der Viszeralchirurgie – Onkologische Chirurgie. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     
  530. Lordick F, Hölscher AH (2010). Esophageal Cancer. In: Blanke, Roedel, Talamonti, Gastrointestinal Oncology, a Practical Guide. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     


    531. 2009


  531. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Hofler H, Keller G (2009). CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer, 45(18), 3326-3335.
     
  532. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Muller L, Rothling N, Peschel C, Langer R, Lordick F (2009). Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 20(10), 1667-1673.
     
  533. Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F (2009). Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Onkologie, 32(1-2), 30-34.
     
  534. Lordick F (2009). [Multidisciplinary treatment for adult soft tissue sarcoma]. Chirurg, 80(3), 209-215.
     
  535. Lordick F, Ott K (2009). Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzinoms. Der Gastroenterologe, 4(3), 224-231.
     
  536. Ott K, Lordick F (2009). [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg, 80(11), 1028-1034.
     
  537. Lordick F (2009). [Principles of neoadjuvant therapy]. Chirurg, 80(11), 1000-1005.
     
  538. Czito B, Lordick F (2009). Accomplishments in 2008 in the adjuvant treatment of rectal cancer. Gastrointest Cancer Res, 5(Suppl 2), 8-14.
     
  539. Apostolidis L, Kahlert C, Siegmund A, Thom R, Horstmann S, Jager D, Lordick F (2009). Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. Onkologie, 32(1-2), 50-53.
     
  540. Berger AK, Bellos F, Siegmund A, Eisenbach C, Lordick F (2009). Symptomatic hyponatraemia caused by cylophosphamide. Onkologie, 32(5), 280-282.
     
  541. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K (2009). Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol, 22(12), 1555-1563.
     
  542. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR (2009). Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol, 16(4), 1017-1025.
     
  543. Ott K, Lordick F, Molls M, Bartels H, Biemer E, Siewert JR (2009). Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg, 96(3), 258-266.
     
  544. Rosenberg R, Herrmann K, Gertler R, Kunzli B, Essler M, Lordick F, Becker K, Schuster T, Geinitz H, Maak M, Schwaiger M, Siewert JR, Krause B (2009). The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis, 24(2), 191-200.
     
  545. Cmelak AJ, Lordick F, Borner M, Goldberg RM, Saif MW (2009). Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston Park), 23(2 Suppl1), 18-25.
     
  546. Lordick F, Sendler A (2009). Magenkarzinom. In: Schmoll & Arnold, Therapiekonzepte bei gastrointestinalen Tumoren. (S. ), Bremen: Uni-Med Verlag.
     


    547. 2008


  547. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ (2008). Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res, 14(7), 2012-2018.
     


    548. 2007


  548. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U (2007). Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer, 55(1), 109-113.
     
  549. Siewert JR, Molls M, Zimmermann F, Lordick F (2007). Clinical Management. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, Gastrointestinal Oncology. Principles and Practice. (S. ), Philadelphia: Lippincott Williams & Wilkins.
     
  550. Lordick F (2007). Therapiestrategien bei Patienten mit synchron metastasierten kolorektalen Karzinomen. In: Bokemeyer, Das kolorektale Karzinom – Grundlagen, Prävention und moderne Therapiekonzepte. (S. ), : SocioMed Verlag .
     
  551. Sendler A, Lordick F, Tannapfel A (2007). Das Magenkarzinom. In: Hiddemann W, Onkologie. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     


    552. 2006


  552. Siewert JR, Lordick F (2006). Standards in der interdisziplinären Diagnostik und Therapie. In: Schmoll, Höffken, Possinger, Kompendium Internistische Onkologie. (S. 000), Heidelberg, Berlin, New York: Springer Verlag.
     
  553. Zimmermann F, Meining A, Lordick F, Sarbia M (2006). Ösophagus-Plattenepithelkarzinom. In: Sendler A , Manual Gastrointestinale Tumoren des Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge (S. 1-18), München: Zuckschwerdt-Verlag.
     
  554. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, Lordick F, Schuhmacher C, Zimmermann F (2006). Magenkarzinom. In: Sendler A , Manual Gastrointestinale Tumorendes Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. (S. 26-53), München: Zuckschwerdt-Verlag.
     
  555. Nieder C, Lordick F (2006). Combination of platinum compounds and ionizing radiation. In: Brown JM, Mehta MP, Nieder C, Multimodal Concepts for Integration of Cytotoxic Drugs and Radiation Therapy. (S. ), Berlin, Heidelberg, New York : Springer Verlag.
     
  556. Zimmermann F, Meining A, Lordick F, Sarbia M, Brücher B (2006). Ösophagus-Plattenepithelkarzimom. In: Tumorzentrum München, Manual des Tumorzentrums München. (S. ), München Wien New York: Zuckschwerdt-Verlag.
     
  557. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, Lordick F, Schuhmacher C, Zimmermann F (2006). Magenkarzinom. In: Tumorzentrum München, Manual des Tumorzentrums München. (S. ), München: Zuckschwerdt-Verlag.
     
  558. Peschel C, Lordick F (2006). Therapie-induzierte Nausea und Emesis in der Onkologie. In: Lordick F, Therapie-induzierte Nausea und Emesis in der Onkologie. (S. ), Bremen, London, Boston.: Uni-Med Verlag.
     


    559. 2005


  559. Siewert JR, Stein HJ, Lordick F (2005). Ösophaguskarzinom. In: Siewert JR, Rothmund M, Schumpelick V , Praxis der Viszeralchirurgie: Onkologische Chirurgie. (S. 445-481), Berlin, Heidelberg, New York: Springer Verlag.
     
  560. Siewert JR, Sendler A, Lordick F (2005). Magenkarzinom. In: Siewert JR, Rothmund M, Schumpelick V , Praxis der Viszeralchirurgie: Onkologische Chirurgie (S. 403-433), Berlin, Heidelberg, New York: Springer Verlag.